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The epidermal growth factor receptor (EGFR) family member ErbB2 (Her2) is
overexpressed in 20 -30% of invasive breast cancers and this overexpression correlates
with poor prognosis and shorter overall as well as disease-free survival. Aberrant
expression of ErbB2 through gene amplification, transcriptional deregulation and/or
altered endocytic trafficking results in overexpression of ErbB2 at the plasma membrane
and biases ErbB2 from primarily ligand-driven hetero-dimerization under normal
expression conditions to increased ligand-independent homo-dimer and hetero-dimer
formation and consequent activation. C-terminus of HSC70-Inteeracting protein
(CHIP)/STIP1-homologous U-Box containing protein 1 (STUB1) is an HSP90/HSC70
interacting negative co-chaperone known to promote ubiquitination and degradation of
unfolded proteins, playing an essential role in protein quality control. HSP90/HSC70 are
required for the stability and function of a variety of signaling proteins, including a
number of protein kinases and their downstream signaling components. It is now known
that CHIP can function as an E3 ubiquitin ligase towards such HSP90/HSC70 clients to
induce their ubiquitination and degradation. ErbB2 is a prominent receptor tyrosine
kinase that is dependent on its continuous association with HSP90 for its stability and
function as an oncogene. Thus, CHIP, acting as an E3 ubiquitin ligase towards ErbB2
and its downstream signaling proteins has been hypothesized to function as a tumor

	
  
suppresser. Consistent with this idea, recent work indicates that CHIP mRNA and
protein expression is reduced in a subset of breast cancers, primarily those that are
estrogen-receptor negative and belonging to ErBB2+ and triple-negative subsets. How
CHIP functions as a tumor suppressor in breast cancer in general and in ErbB2+ breast
cancer in particular, has not been fully elucidated. In this thesis, we identify two interconnected and novel mechanisms by which CHIP suppresses ErbB2-mediated breast
oncogenesis. First, we demonstrate that CHIP targets newly synthesized
HSP90/HSC70-associated ErbB2 for in the Endoplasmic Reticulum and Golgi for
ubiquitin/proteasome-dependent degradation to negatively control the levels of cell
surface ErbB2. Second, by analyzing CHIP expression in tissue microarrays from a
large and well-annotated cohort of breast cancer patient samples, we identified a series
of transcription factors whose cognate DNA-binding activity is up- or down-regulated by
CHIP. We identify Myeloid Zinc Finger 1 (MZF-1), a transcription factor that
transcriptionally upregulates the expression of extracellular matrix degrading enzymes
cathepsin B and cathepsin L (CTSB/L) as a target of direct CHIP-dependent
ubiquitination and degradation as well as indirect inhibition through reduced
transcription. Small hairpin RNA (shRNA)-mediated depletion of CHIP in ER+ breast
cancer cells or ectopic overexpression of CHIP in ErbB2 in ErbB2+ and triple-negative
breast cancer cells demonstrated that loss of CHIP in the two latter subtypes of breast
cancer is a principal determinant of MZF1-dependent upregulation of CTSB/L expression
and activity, increased cell migration, invasiveness and matrix degradation, anchorageindependent growth in soft agar, and xenograft tumor formation and metastasis in vivo.
Targeting of CTSB using specific chemical inhibition lead to statistically-significant tumor
growth inhibition with reduced angiogenesis, correlating with inhibition of matrix
degradation in vitro, suggesting altogether a potentially new therapeutic avenue to
improve metastatic breast cancer treatment by targeting those tumors with reduced
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CHIP expression for cathepsin inhibitor therapy in conjunction with conventional and
ErbB2-targeted therapeutics.
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Chapter 1: Introduction
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1.1 Protein maturation
1.1.1. Protein folding in the Endoplasmic Reticulum (ER)
Proteins destined for secretion or residence in the plasma membrane, Golgi
apparatus, lysosomes, or ER are first translocated into the ER. Translocation of most
polypeptides into the ER lumen occurs through the Sec61 protein channel (1). Targeting
of soluble ER proteins and Type Ⅰ membrane proteins is achieved by an N-terminal
signal sequence. As these polypeptides enter the ER lumen co-translationally in an
extended conformation, chaperones start to function and help them fold correctly.
Binding immunoglobulin protein (BiP), also called glucose-regulated protein 78 (Grp78),
is a member of the Hsp70 family of proteins and the major ER luminal chaperone. Like
cytoplasmic chaperones, BiP maintains the polypeptides in a folding-competent
conformation and prevents their aggregation. It is one of the first proteins that meets
nascent polypeptides entering the ER along with other chaperones that are preassembled into a complex. This complex is poised to interact with the polypeptides being
translocated into the ER and prevents the nascent chain from slipping backwards into
the cytoplasm. Proteins containing the N-linked glycosylation consensus sequence
(asparagine-X-serine/threonine, where X is any amino acid except proline) are
recognized by the oligosaccharide transferase (OST) complex as the polypeptide exits
the translocon on the luminal side. Glycosylation increases the protein’s solubility, helps
folding, and increases the stability of folded protein. The OST complex catalyzes the
transfer of pre-assembled Glc3Man9GlcNAc2 (Glucose3, Mannose9, Nacetylglucosamine2) from dolichol pyrophosphate onto the asparagine residue of the
glycan acceptor of the polypeptide. Once glycans are covalently attached to
polypeptides, the two outer glucose residues are removed by Glycosidase Ⅰ and Ⅱ. This
produces a Glc1Man9 GlcNAc2 glycan structure which is preferentially bound by the
lectin chaperones calnexin and calreticulin. Calnexin and calreticulin recruit ERp57, an
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enzyme that catalyzes one of the rate-limiting steps of protein folding, the disulfide bond
formation. Binding of calnexin and calreticulin to polypeptide chains also provides time
for polypeptides to fold and serves as an ER retention mechanism. When calnexin
releases the glycan, glycosidase Ⅱ removes the third and final glucose moiety. If the
glycoprotein is correctly folded by this time, it is allowed to continue its progression
through the secretory pathway. If the polypeptide has failed to fold correctly, it will be
either given another chance to attempt folding or will be marked for removal from the ER
and be degraded through ubiquintin-proteasome system (UPS). Re-entry into the
calnexin/calreticulin cycle is achieved by re-glycosylation of the glycan by UDP-glucose:
glycoprotein glycosyltransferase (UGGT)(2, 3)(Figure 1.1).
Once the proteins are correctly folded, native conformers enter ER exit sites.
Vesicles that are coated with the coatomer protein (COP) Ⅱ coat bud off and traffic
through the ER-Golgi intermediate compartment (ERGIC) to the cis-face of the Golgi
complex (4). In certain cases, the retrieval of misfolded proteins from the Golgi complex
by COP Ⅰ vesicles has been observed (5). The Golgi complex does not contain
molecular chaperones and does not seem to support protein folding. Once the proteins
pass through the cis-Golgi, they proceed through the trans-Golgi network (TGN) to the
plasma membrane or beyond (Figure 1.2).

1.1.2. Endoplasmic Reticulum Associated Degradation
Terminally misfolded or unassembled proteins that are unable to acquire their
native structure must be degraded to prevent fruitless folding attempts and the
accumulation of misfolded polypeptides in the ER. This degradation process is known as
ER-associated degradation (ERAD), which occurs in three primary steps: (1) recognition
and targeting (substrate recognition within the ER and targeting to the retro-translocon),
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(2) retro-translocation (substrate delivery from the ER to the cytosol), and (3)
degradation (ubiquitin–proteasome dependent degradation)(6).
The recognition of misfolded or mutated proteins depends on the detection of
substructures within proteins such as exposed hydrophobic regions, unpaired cysteine
residues, and immature glycans. In mammalian cells, there exists a mechanism called
glycan processing. In this mechanism, the lectin-type chaperones calnexin/calreticulin
(CNX/CRT) provide immature glycoproteins the opportunity to reach their native
conformation. They can do this by way of re-glucosylating these glycoproteins by an
enzyme called UDP-glucose-glycoprotein glucosyltransferase. Terminally misfolded
proteins, however, must be extracted from CNX/CRT. This is carried out by EDEM (ER
degradation-enhancing α-mannosidase-like protein) and ER mannosidase I. The
mannosidase removes one mannose residue from the glycoprotein and the latter is
recognized by EDEM. Eventually EDEM will target the misfolded glycoproteins for
degradation.
Because the ubiquitin–proteasome system (UPS) is located in the cytosol,
terminally misfolded proteins have to be transported from the endoplasmic reticulum
back into cytoplasm. The protein complex Sec61 is a possible channel for the transport
of these misfolded proteins, however it is an unlikely candidate as retro-transport
through the complex is difficult. It is unknown which other membrane protein(s) is
responsible for this transport. Further, this translocation requires a driving force that
determines the direction of transport. Since poly-ubiquitination is essential for the export
of substrates, it is likely that this driving force is provided by ubiquitin-binding factors.
One of these ubiquitin-binding factors is the Cdc48p-Npl4p-Ufd1p complex in yeast.
Humans have the homolog of Cdc48p known as valosin-containing protein (VCP/p97)
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with the same function as Cdc48p. VCP/p97 helps transport substrates from the
endoplasmic reticulum to the cytoplasm using its ATPase activity.

1.1.3. Ubiquitin proteasome system
Ubiquitin itself is a highly conserved 76 amino acid protein which covalently
attaches to substrate proteins through the formation of an isopeptide bond between
ubiquitin’s C-terminal carboxyl function and in most studied cases the ε-amino group of a
lysine residue within the substrate protein. In eukaryotes, ubiquitin is abundant with
levels around 0.1-5% of total cellular proteins (7). Ubiquitin forms a globular structure
and is very stable. The transfer of a single ubiquitin to a substrate, a reaction referred to
as mono-ubiquitylation, typically alters interactions, localization or activity of the modified
substrate. Conversely, the attachment of multiple ubiquitin molecules results in
polymeric chains, which, depending on their connectivity, could have unique functions.
Ubiquitin chain formation can occur through seven lysine residues (K6, K11, K27, K29,
K33, K48 and K63) or the N-terminus of ubiquitin (M1), leading to the assembly of
multiple chains with distinct topology; the use of different lysine residues leads to more
complex ubiquitin topologies. All linkage variants have been detected in cells and their
abundance changes during the cell cycle or cell differentiation (8, 9).
Most ubiquitination reactions occur through the subsequent actions of an
adenosine triphosphate (ATP)-dependent enzymatic cascade consisting of ubiquitin
activating enzymes (E1), ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3).
Two ubiquitin specific E1s exist in vertebrates called UBA1 and UBA6. The human
genome contains about forty E2s. More than six hundred distinct E3s ensure the
regulated modification of specific substrates within human cells (10).
As shown in Figure 1.3, the initial step in the ubiquitination cascade is the binding
of Mg•ATP and ubiquitin to E1. Next, ubiquitin is adenylated at its C-terminus by E1 with
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release of pyrophosphate (PPi). E1’s catalytic cysteine sulfhydryl group attacks the
ubiquitin adenylate bond leading to discharge of adenosine monophosphate (AMP) and
the formation of a thioester between E1 and ubiquitin’s C terminal carboxyl group.
Another round of ubiquitin adenylation leads to a complex of E1 bound to the activated
ubiquitin adenylate and the thioester ubiquitin intermediates. This single E1 bound to two
activated ubiquitin species binds E2s with nanomolar affinities. Ubiquitin is then
transferred to the catalytic site cysteine residue of the respective E2 in a trans-thioesterification reaction. The ubiquitin charged E2 dissociates from E1, which now can
undergo another cycle of ubiquitin thioester and subsequent ubiquitin adenylate
formation. An E3 will bind an E2 loaded with ubiquitin and catalyze ubiquitin transfer
from the E2’s active site onto the substrate forming a stable isopeptide bond between
ubiquitin’s C terminal carboxyl group and a ε-amino group of a lysine residue of the
respective substrate (11). This process can be repeated multiple times resulting in the
formation of polyubiquitin chains on a substrate; engagement of the substrate already
modified with ubiquitin by an E3 causes the addition of another ubiquitin moiety from an
E2 leading to formation of a covalent bond between the C-terminus of E2 bound
ubiquitin and a lysine residue of the substrate attached ubiquitin (12). E3 binding sites in
substrates are called degrons if the E3 promotes substrate degradation. The
determinants of E2/E3 pairing are further elaborated below. E3s can be divided in two
major classes: really interesting new gene (RING) and homologous to E6-AP carboxy
terminus (HECT) ligases. Ubiquitin ligases that further ubiquitylate oligoubiquitylated
substrates are called E4s.
The human 26S proteasome is responsible for ubiquitin-dependent protein
degradation in the ubiquitin proteasome system (UPS) (13). It consists of the proteolytic
20S core particle (CP) and a 19S regulatory particle (RP). The CP consists of 28
subunits encoded by 14 different genes and is shaped like a barrel in a symmetrical
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manner (14, 15). The interior of the barrel is coated with six peptidase active sites, which
together are able to hydrolyze a wide range of proteins into oligopeptides (14, 15). Entry
into the inner chamber of the CP is regulated by the RP (13). The RP consists of 19
subunits in yeast and can be further subdivided into base and lid. Six different ATPases
responsible for CP-RP complex formation, two scaffold proteins and two ubiquitin
binding proteins, the 26S proteasome regulatory subunits Rpn10/S5a and Rpn13 (also
called ubiquitin receptors), make up the base. ATP binding to the ATPases is necessary
for proper assembly of the complex formations. ATP hydrolysis is required for protein
unfolding and translocation of the unfolded polypeptide via a channel into the proteolytic
chamber of the CP (13). The only assigned function for one of the nine lid subunits is the
deubiquitinase (DUB) activity of Rpn11, which is important for proteasome activity
cleaving off a ubiquitin chain in one step at the proximal ubiquitin. Consequently, the
concerted actions of CP and RP enable the 26S proteasome to bind a ubiquitylated
protein via its ubiquitin receptors, to unfold the protein with its ATPases, to cleave off
ubiquitin with its DUB and to translocate the unfolded protein into the inside of the CP,
where its peptidases hydrolyze the proteins. Several other proteins bind the proteasome,
regulating its function. The ATP-driven chaperone valosin-containing protein/p97 (p97)
has been implicated in targeting ubiquitylated proteins to the proteasome as well (16,
17). In complex with its cofactors, which have ubiquitin binding domains, p97 is able to
interact with ubiquitylated proteins (17, 18). Using its so-called “segregase” activity, p97
can extract proteins from the ER or the mitochondrial membrane as well as chromatin for
proteasomal degradation; it has also been shown to be involved in the clearance of
intracellular protein aggregates, in autophagy and in endosomal trafficking (19).

1.2 Molecular Chaperones
1.2.1. Hsp70 family
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The Hsp70 family is one the most ubiquitous and conserved classes of

chaperones, existing in almost all living organisms. The sequence identity between
prokaryotic Hsp70, DnaK, and its eukaryotic homologues is around 60% (20). In
eukaryotes, Hsp70s are found in the cytosol, mitochondria (mtHsp70), chloroplasts
(cpHSC70), and ER (Grp78/Bip) (21). In mammals, there are two isoforms of cytosolic
Hsp70, constitutively expressed Hsc70 and stress-inducible Hsp70. Hsp70 is composed
of three structural domains, a 44 kDa N-terminal ATPase domain followed by an 18 kDa
substrate binding domain (SBD) and a 10 kDa C-terminal domain (22). Clients interact
with the hydrophobic pocket in the SBD, and the interaction is profoundly affected by the
interaction between Hsp70 and nucleotides. In the ATP bound-state, Hsp70 has a low
affinity but fast exchange rate, while the ADP bound-state shows high client affinity but
slow exchange rates (22, 23). Moreover, the position of the C-terminal lid is different. In
the ADP-bound state, the lid moves closer to the SBD, which prevents the release of
client protein (24, 25). Hsp70s facilitate not only the protein folding or refolding, but also
the degradation and translocation. To achieve these functions, Hsp70 works together
with J-proteins (Hsp40s) and nucleotide exchange factors. These co-chaperones
regulate the Hsp70 machinery by either conferring client specificity or affecting the
interaction with nucleotides.
The Hsp70 chaperone machine does not always act alone, but also cooperates
with other chaperone machines. For example, in the folding of nascent polypeptides,
Hsp70 interacts with unfolded clients and then transfers them to the Hsp90 chaperone
machinery through the adaptor protein Hop (Hsp70-Hsp90 Organizing Protein) for final
maturation and activation (26). Hsp70 forms an early complex with client proteins, Hop
binds to the open conformation of Hsp90 and acts as the attachment site for Hsp70
bound client protein. Hop facilities the transfer of the client protein from Hsp70 to Hsp90
and the intermediate complex is formed. Hsp90 converts to the closed conformation
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after binding of ATP and p23. After the hydrolysis of ATP, p23 and the folded client
protein are released from Hsp90 (25, 27).

1.2.2. Hsp90 family
Hsp90 is a highly conserved molecular chaperone that is essential in eukaryotes
(28, 29)，and is one of the most abundant proteins, even in unstressed cells (30, 31). It
contributes to various cellular processes including signal transduction, protein folding,
intracellular transport, and protein degradation.
Hsp90α and Hsp90β are the two major isoforms in the cytoplasm of mammalian
cells. Hsp90α is the major form which is inducible under stress conditions, while Hsp90β
is constitutively expressed (32, 33). Hsp90 analogues also exist in other cellular
compartments such as Grp94 in the endoplasmic reticulum and Trap-1 in the
mitochondrial matrix.
One thing of note is that Hsp90 is highly overexpressed in cancer cells (34, 35).
They utilized the Hsp90 machinery to protect mutationally-activated and overexpressed
oncoproteins from misfolding and degradation, thereby contributing to tumor survival.

1.3 The ErbB family of receptor tyrosine kinases
1.3.1. Structure of ErbB receptors
The Epidermal Growth Factor Receptor (EGFR) family of receptor tyrosine
kinases (RTK) consists of four members: EGFR (ErbB1, HER1), ErbB2 (HER2; Neu in
rat), ErbB3 (HER3), and ErbB4 (HER4). They are all Type I class of receptors, sharing
similar structural characteristics including an extracellular ligand binding domain, a single
pass hydrophobic transmembrane domain, a highly conserved catalytic protein tyrosine
kinase (TK) core followed by a carboxyl terminal stretch containing several critical
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tyrosine residues (36). The extracellular region of the ErbB family of RTKs is comprised
of four distinct subdomains: two homologous ligand-binding domains (I and III) and two
cysteine-rich domains (II and IV). One function of subdomains II and IV is to maintain an
auto-inhibited configuration through intramolecular contacts, thereby forcing subdomains
III and I into a relative orientation that prevents high-affinity binding of a ligand. Once a
ligand binds to sub domains I and III, this alters the configuration of the extracellular
region and exposes a dimerization arm located in sub domain II, thus allowing it to make
intermolecular links with an adjacent receptor and driving dimerization (37). The tyrosine
kinase domain is responsible for the transfer of a phosphate group from an ATP
molecule to a tyrosine residue on a protein substrate. As mentioned above, the most
highly conserved region within all ErbB family members, as is the case with most other
RTKs in general, is the tyrosine kinase domain. One exception however is the ErbB3
protein. This receptor shares the least sequence identity with the other ErbB receptors,
including residues that are critically conserved throughout all protein kinases, thus
rendering it catalytically inactive (38). The carboxyl-terminal tail sequences are among
the most divergent between ErbB receptors (39). Sequence alignment comparing the
carboxyl-terminus shows the highest level of conservation between the EGFR and
ErbB2 receptors, particularly in the several tyrosine autophosphorylation sites that have
previously been mapped in the carboxy-terminus of the EGFR and ErbB2. It is these
phosphorylated residues that are recognized and bound by specific intracellular proteins,
thereby initiating a highly coordinated signal cascade (40). All ErbB receptors other than
EGFR are endocytosis-resistant after ligands binding (41).

1.3.2. Activation of ErbB receptors
Typically, ErbB receptors are activated by a number of ligands, adding to the
potential and diversity of ErbB signaling responses (42). Each ligand, now commonly
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referred to as EGF-like peptide, has an EGF-like domain that is sufficient to confer
unique specificity for its receptor substrate and they have the ability to modulate the
catalytic activity of the receptor. Most of these ligands act over short distances as
autocrine or paracrine factors and their availability or expression pattern in a tissuespecific or developmental stage-specific pattern offer a level of control over their
signaling potential. The EGF-like peptides are divided into three groups based on their
specificity: epidermal growth factor (EGF), amphiregulin (AR) and transforming growth
factor-a (TGF-a) specifically activate EGFR (43); betacellulin (BTC), heparin-binding
EGF (HB-EGF) and epiregulin (EPR) exhibit dual specificity for EGFR and ErbB4 (40);
and the neuregulins (NRG) bind to both ErbB3 and ErbB4 (44). No direct soluble ligand
for ErbB2 has been identified to date and it remains an orphan receptor. In fact,
structural analyses of the ectodomain of ErbB2 suggest that it may not require ligand
binding and remains in a conformation that is conducive to oligomerization. However,
there have been reports suggesting that a member of the Mucin family known as
Muc4/sialomucin may act as an unconventional intramembrane ligand for ErbB2 (45-47).
Interestingly, Muc4/sialomucin contains EGF-like domains that are similar in sequence to
the EGF-like domains in the NRG ligands (48) and is capable of activating ErbB2 leading
to limited ErbB2 phosphorylation as well as inducing the translocation of ErbB2 from the
basolateral surface to the apical surface in polarized epithelial cells (49, 50). Also, ErbB2
is the only receptor that needs Hsp90 binding for its stability even in its fully mature state
and at the cell surface.

1.3.3. ErbB2 and breast cancer
Elevated expression of the ErbB receptors has been observed in clinical studies
of a significant number of sporadic breast cancers (51). Indeed, overexpression of EGFR
in mammary carcinomas inversely correlates with patient outcome (52). Furthermore, a
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limited number of studies relating the ErbB3 receptor with human breast cancer have
concluded that approximately 22% of cases involved elevated levels of ErbB3, however
there was no evidence that this was the result of gene amplification. Other studies
suggest that ErbB3 may be a culprit along with ErbB2 in breast cancer by relating the
coincidental elevated co-expression of ErbB2 and ErbB3 in mammary tumors (53) or the
requirement for both ErbB2 and ErbB3 to drive breast tumor cell proliferation.
To this end, a number of clinical studies have estimated that amplification and
overexpression of the erbB2 is involved in about 20-30% of human breast cancer (5458). The consequences of this have been correlated with a poor clinical prognosis for the
patient with increased chance of relapse and death (54, 55, 59-61). Consistent with
other receptors, activating mutations seem to only play a minor role in ErbB2-related
human cancers. It should be noted however that despite the identification of the V664E
activating mutation in the sequence of the rat Neu transmembrane region (62), a
comparable mutation has not been found in human ErbB2. Instead, mutations, when
found, are within the kinase domain. Thus, it appears that expression of erbB2 to
elevated levels either through gene amplification or deregulated expression of wild type
erbB2 is the primary mechanism of ErbB2-driven oncogenesis. Notably, an alternatively
spliced isoform of ErbB2 was detected in human breast tumor samples and this mutant
receptor displays elevated catalytic activity in vitro (63). The alternate splicing results in
an ErbB2 receptor that is strikingly similar to the activating deletion mutations identified
in Neu-induced murine tumors, which have a higher propensity to dimerize (53, 64).
However, the exact role and function of the alternatively spliced ErbB2 receptor in the
normal mammary gland and/or in mammary oncogenesis is not clear at this point..

1.4 Carboxyl terminus of Hsp70-interacting protein (CHIP)
1.4.1. Structure of CHIP
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CHIP, also known as STUB1 (STIP1-homologous U-Domain-containing protein

1; STIP1 is an alternative name for Hop) was discovered in an attempt to identify novel
TPR-containing proteins in the human heart. In these studies, a fragment of the human
CyP-40 (cytochrome P-40) cDNA, corresponding to its TPR domain-encoding
nucleotides 721 to 1150, was radiolabeled with [α-32P] dCTP and used to screen a
phage library of human heart cDNAs at low stringency (65). CHIP cDNA encodes a 34.5kDa protein. Evolutionarily, CHIP is a well-conserved protein with an amino acid
sequence similarity of ~98% with mouse and ~60% with the fruit fly (66). Intracellularly,
CHIP was found to primarily localize to the cytoplasm under quiescent conditions (65)
although a fraction of CHIP was later found to be present in the nucleus as well (67).
CHIP is an E3 ubiquitin ligase, has two characteristic domains, one the
tetratricopeptide repeats (TPRs) at its amino terminus, which serves as the proteinprotein interaction domains, interacting in particular with heat shock proteins (Hsp70,
Hsc70 and Hsp90) through binding to their conserved c-terminal “EEVD” motifs. Another
important and unique domain is the U-box domain at the carboxyl-terminus region. The
U-box domain was first recognized in yeast Ufd2 protein, which perform “E4” activities.
Moreover, the tertiary structure of U-box resembles that of the RING finger domain,
which is responsible for E3 activities for a large family of ubiquitin ligases (68). Also,
CHIP participates in ubiquitinated substrate delivery to the proteasome by interacting
with the S5a proteasome subunit. Therefore, CHIP protein mediates interactions
between the chaperone system and the ubiquitin-proteasome system (69-72).

1.4.2. CHIP in protein quality control
The classical role of chaperones was initially regarded as those of folding and
salvaging proteins. However, it became clear that each and every newly synthesized
polypeptide that engages with chaperones for its folding could not reach a native state,
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and thus there must be a link between the chaperones and the degradation pathways.
CHIP provides that link. CHIP was shown to inhibit the forward cycle of chaperones.
However, the actual role of CHIP became clarified when it was shown to have intrinsic
E3 ligase activity owing to the C-terminal U-box. Experimental studies with increased
cellular levels of CHIP found a marked shift towards degradation of the HSP90/HSC70
clients, glucocorticoid receptor (GR) (65, 73), ErbB2 (74, 75), serum-and glucocorticoidregulated kinase (SGK1) (76) and CFTR (77, 78). Definitive evidence for a quality
control role of CHIP was provided when it was shown to selectively promote the
ubiquitination of thermally denatured luciferase (and not the native form) when captured
by Hsc70 and Hsp90 (70, 71, 79). That CHIP may participate in protein turnover was
hinted by initial observations depicting a relatively higher expression of CHIP mRNA in
tissues with a large proportion of terminally differentiated, non-proliferating cells and high
levels of metabolic activity such as skeletal muscle, heart, and brain (65). The
physiological importance of CHIP came into light with the observations that ~20% of
CHIP null (CHIP − /−) mice die at embryonic stages and 100% fail to survive thermal
stress (80).
CHIP was previously shown to cooperate with the UbcH5 family of E2s to
catalyze Lys-48-linked poly-ubiquitination. UbcH5 is a stress-associated E2. UbcH5~Ub
conjugates have been shown to adopt both infinite spiral and linear staggered (backside
interaction) arrangements. Interestingly, CHIP can directly interact with four (or more)
UbcH5~Ub conjugates allowing wide conformational flexibility during poly-ubiquitination
of substrates (81). One consequence of this is the possibility of formation of forked
ubiquitin chains.
Later, Xu and coworkers (82) reported CHIP to interact with the dimeric ubiquitin
E2 complex Ubc13-Uev1A, which catalyzes the synthesis of Lys-63-linked polyubiquitination. They analyzed crystal structures of mouse CHIP U-box in complex with
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Ubc13-Uev1a and found a common “Ser-Pro-Ala” motif present in UbcH4, UbcH5, and
Ubc13 that mediates, and is necessary for, their interaction with the CHIP U-box.
Although the catalysis of K63-linked poly-ubiquitination is an inherent structural feature
of Ubc13-Uev1A, it is not clear at present how the binding of CHIP to Ubc13-Uev1A
facilitates the process. Interestingly, CHIP only stimulates the formation of free K63-polyubiquitin by Ubc13-Uev1a and thus may have to interact sequentially with other E2
enzymes to attach K63-linked poly-ubiquitin chains on substrates. CHIP binds 3- to 5fold more strongly to uncharged Ubc13 than UbcH5a. It remains to be seen whether
CHIP displays similar relative binding affinities towards ubiquitin charged E2s.

1.4.3. CHIP in breast cancer
Kajiro et al. (83) showed that CHIP mRNA and protein expression was reduced
in a small fraction of breast cancer patient tumors that were predominantly estrogen
receptor (ER)-negative. In vitro and xenograft studies with cell lines expressing high or
low CHIP indicated that CHIP is an important negative modulator of breast tumor
progression. Subsequently, a number of studies have connected CHIP expression
differences to breast and other cancers. Interestingly, there seems to be a dispute
regarding the oncogenic or tumor suppressive role of CHIP. It was reported that tumor
growth and metastasis were negatively correlated to CHIP levels in a nude mouse
xenograft model of breast tumor. CHIP also seemed to regulate the levels of a number
of well-known oncogenic proteins like the steroid receptor coactivator SRC- 3 and inhibit
anchorage-independent cell growth and migration. Supporting this finding, some of the
later studies reported CHIP to negatively regulate breast tumor promoting proteins like
TRAF2, NF-kB, PTK6, and MIF (macrophage inhibitory factor). These studies also
documented inhibition of various oncogenic properties of breast tumor cells such as
MCF7 and MDA-MB-231 (84-86). Further supporting its role as a tumor suppressor,
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CHIP has been reported to degrade a number of other critical oncoproteins such as pAkt
(87, 88), c-Myc (89), HIF-1 (90, 91) and ErbB2 (74, 75, 92) in various cancers. Patani et
al. (93) assessed the mRNA expression of CHIP in normal and malignant breast tissues
and correlated with clinico-pathological characteristics. They found a striking decrease of
CHIP expression with increasing malignant grades (TNM stages). Further, the overall
patient survival for low CHIP-expressing tumors was significantly lower than high CHIPexpressing tumors. This study identified CHIP as an important favorable prognostic
marker (93). However another study suggested that expression of CHIP was a negative
prognostic factor for breast cancer (92). It is known that chaperones (Hsp70 and Hsp90)
are overexpressed in cancers and many cancer are addicted to these proteins. Indeed,
many phase III clinical trial drugs are specific inhibitors of chaperones (35, 94). The cochaperones HOP Hop and CHIP compete with each other for chaperone binding and
exert mutually opposite effects on chaperone function. While CHIP tilts the balance
toward pro-degradation pathway, Hop favors a pro-folding outcome. Consequently, an
understanding of the relative levels of co-chaperones Hop and CHIP is of importance.
Another group observed higher expression of Hsp70, Hsp90, and Hop in colorectal
cancer. They demonstrated that like Hsp70 and Hsp90, Hop (but not CHIP) is a
transcriptional target of HSF1 which itself is upregulated in cancers, thus forming a
positive feedback pro-carcinogenic circuit. Further, the ratio of Hop to CHIP was
suggested to be a better prognostic marker than individual levels of either protein.
Seemingly, the downregulation of CHIP is an independent event necessary for the
realization of this circuit (95). In yet other interesting study, mRNA and protein levels of
CHIP were found to be significantly lower in more than 75% of gastric tumors relative to
normal tissue which are in line with previous reports in other cancers (96).
Thus far, the molecular mechanism in which CHIP regulates oncoproteins and
suppresses oncogenesis is still largely unknown. In particular, there is paucity of

	
  
information on key CHIP-regulated molecular pathways that contribute directly to
oncogenic traits and can be targeted for therapy. Studies presented in this study were
aimed to elucidate the role of CHIP in ErbB2+ breast cancers with a focus on identifying
therapeutically-targetable pathways.
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Figure 1.1. Schematic of protein maturation in the ER.
(A) Protein folding in the ER. (B) The ER to Golgi apparatus trafficking.
Adapted from Ellaaard L. and Helenius A., (97) .
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Figure 1.2. Schematic of ubiquin cascade and proteasome-mediated protein
degradation
Ubiquitination is carried out in three main steps; activation, conjugation and
ligation. Ubiquintin-tagged substract is transported to proteasome for degradation.
Adapted from Yoshida Y. et al., (98).

	
  

21

	
  

22

Chapter 2: Materials and methods
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2.1 Cell lines and medium
ErbB2-overexpressing breast cancer cell lines SKBR3 and BT474 were cultured
in complete α-MEM medium with 5% fetal bovine serum, 10 mM HEPES, 1 mM each of
sodium pyruvate, nonessential amino acids and glutamine, 50 µM 2-ME, and 1%
penicillin/ streptomycin (Life technologies, Carlsbad, CA). ErbB2-overexpressing breast
cancer cell line 21MT1 cells, obtained from Dr. Vimla Band, was cultured in α-HE
medium (α-MEM medium supplemented with 1 µg/mL hydrocortisone and 12.5 ng/mL
epidermal growth factor (Sigma-Aldrich, St. Louis, MO)) (99). The lentiviral packaging
cell line TSA-54, the ER+ breast cancer cell line MCF7 and the ErbB2-negative and
estrogen receptor/progesterone receptor-negative (triple-negative) breast cancer cell line
MDA-MB-231 was cultured in complete DMEM medium with 5% fetal bovine serum, 10
mM HEPES, 1 mM each of sodium pyruvate, nonessential amino acids and glutamine,
50 µM 2-ME, and 1% penicillin/ streptomycin (Life technologies, Carlsbad, CA).

2.2 Antibodies and reagents
The following antibodies were used for immunoblotting: Ubiquitin – monoclonal
antibody P4D1 from Cell signaling, Denver, PA; ErbB2 – monoclonal antibody (Cat.
554299) from BD-Pharmingen, San Jose, CA; Phospho-tyrosine - 4G10 monoclonal
antibody from EMD Millipore, Billerica, MA; Hsc70 - B-6 antibody from Santa Cruz
Biotechnology, Santa Cruz, CA; CHIP – Rabbit anti-serum made in the laboratory
through Covance Research Products, Denver, PA (75). CHIP IHC staining was
performed using polyclonal rabbit antibody from Thermo Scientific, Waltham, MA.
ErbB2-specific phosphorylation was assessed using anti-phospho-ErbB2-Y1248
antibody from Cell Signaling Technology, Danvers, MA. Secondary reagents used for
immunoblotting included horseradish peroxidase (HRP)-conjugated Protein A and Rabbit
anti-Mouse HRP (Invitrogen, Carlsbad, CA). ErbB2 immuno-staining was carried out
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using the AF1129 antibody from R&D Systems, Minneapolis, MN, or Alexa Fluor-488 or
647-conjugated mouse anti-human ErbB2 (CD340) monoclonal antibodies (clone 24D2;
cat. 324410 and 3244412, respectively) from Biolegend Inc., San Diego, CA, and Alexa
Fluor -488 or 647 mouse mAb IgG1 (MOPC-21) controls (cat. 400129 and 400130) also
from Biolegend. Secondary antibodies for immunostaining included Alexa Fluor 488
donkey anti-goat IgG for ErbB2 and Alexa Fluor 594 donkey anti-rabbit IgG for phosphoErbB2-Y1248 from Invitrogen Molecular Probes, Eugene, OR. 17-AAG was obtained
from Biomol, Plymouth, PA, and stocks prepared at 10 mg/ml or higher in DMSO.
Trastuzumab (obtained from UNMC pharmacy) was dissolved in Phosphate Buffered
Saline (PBS). Brefeldin A (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO.
Cathepsin B-specific inhibitor CA074 (Sigma-Aldrich, St. Louis, MO) was dissolved in 1%
DMSO in PBS.

2.3 Protein lysis and quantification
Cells were either lysed in Radio-Immuno-Precipitation Assay (RIPA) lysis buffer
(50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton-X-100, 0.05% deoxycholate, 0.1% Sodium
Dodecyl Sulfate (SDS)) with or in Triton-X-100 lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 0.5% Triton-X-100), 1 mM PMSF, 10 mM NaF, and 1 mM sodium orthovanadate.
Lysates were rocked at 4°C for a minimum of 1 hour, centrifuged at 13,000 rpm for 20
minutes at 4°C in a bench-top micro-centrifuge and supernatants were transferred to
fresh tubes. Protein concentrations of samples were estimated using the Bicinchoninic
acid (BCA) assay kit (Thermo Fisher Scientific, Rockford, IL) or the Bradford assay
reagent (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin (BSA) as a
standard.

2.4 Immunoprecipitation (IP) reactions
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Cells were lysed in RIPA buffer. Following the total protein estimation of the

lysate samples, the optimized ratio of total lysate and antibody was allowed to incubate
on a rocker overnight at 4°C. 200 µL of 10% Protein A Sepharose (PAS, GE Healthcare,
Chalfont St. Giles, UK) beads (washed with RIPA buffer) were added to each IP sample
and rocked at 4°C overnight. Following this incubation, the samples were centrifuged for
5 minutes at 13,000 rpm at 4°C, the supernatant was removed to a separate tube, and
the beads were washed five times with 1 m1 of RIPA buffer. Then, 100 µL of 2X sample
buffer (10% glycerol, 3% SDS, 0.02% bromophenol blue, 0.5X Upper Tris [4X Upper Tris
-0.5 M Tris pH 6.8, 0.4% SDS]) was added to each sample, heted at 95oC for 3-5 min,
resolved by SDS-Polyacrylamide (Biorad) Gel Electrophoresis (PAGE), transferred to
Polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA) and
subjected to Western Blotting(75).

2.5 Confocal immunofluorescence microscopy
Cells were grown on glass coverslips inside the wells of a 24-well tissue culture
plate. After the completion of an experiment cells were fixed in 4% paraformaldehyde
(PFA) in PBS for 20 minutes. The PFA solution was removed and the cells were
permeabilized for 20 minutes in immunofluorescence (IF) buffer (10% FBS, 0.2% BSA,
and 0.05% saponin in PBS). The cells were then stained with primary antibodies for
overnight at 4 °C followed by three 10-minute washes in PBS. The cells were then
incubated with the appropriate secondary antibodies for 1 hour (diluted 1:500 in the IF
buffer), followed by three 10-minute washes in PBS. In preparation for confocal
microscopy, PBS was removed and the coverslips were carefully removed and inverted
onto glass microscope slides with Vectashield mounting medium (Vector Laboratories,
Burlingame, CA), which contained 4′, 6-diamidino-2-phenylindole (DAPI) to stain DNA in
the nucleus of the cell. The coverslips were allowed to adhere to the surface and dry for
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5 minutes or more, and then images were captured using a Nikon C1 confocal
microscope.

2.6 Transfection and plasmids
XtremeGENE 9 transfection reagent was from Roche Applied Science
(Indianapolis, IN); siRNA smartpools and Dharmafect I transfection reagent were from
Dharmacon division of Thermo-Fisher (Pittsburgh, PA). Fluorescent Golgi marker
plasmid Pm-Turquoise2-Golgi was purchased from Addgene (plasmid No. 36305).

2.7 35S-methionine/cysteine pulse-labeling followed by chase (pulse-chase)
Cells were grown in 10-cm dishes until sixty to seventy percent confluent. The
medium was removed, cells were washed three times with PBS, and incubated with
methionine- and cysteine-free DMEM medium [cat. 21013-024, Life technologies,
Carlsbad, CA]) for 30 minutes at 37 °C. 35S-labeled methionine/cysteine mixture
(EXPRE35S35S Protein Labeling Mix, cat. NEG772, from Perkin Elmer, Waltham, MA)
was added to a final concentration of 0.5 mCi/ml. After 20 minutes, cells were washed
three times with cold PBS and chased with complete DMEM medium supplemented with
100 fold extra unlabeled methionine and cysteine for various time points with or without
brefeldin-A treatment.

2.8 Analysis of cumulative proliferation
Cells were grown in 6-well plates at a density of 5,000 cells per well. The cells
were counted after seven-day culture and re-plated in fresh 6-well plates at the original
plating density for a total of five serial cultures. The cumulative cell numbers were
calculated based on the fractions of each harvest used for replating and plotted as a
function of the times cells were re-plated.
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2.9 Anchorage-independent growth on soft agar
2,500 cells were seeded in 0.35% soft agar on top of 0.6% soft agar layer in 6well plates. After two weeks, cells were stained with crystal violet and imaged under a
phase contrast microscope. The colonies were enumerated using the Image J (NIH, MD).

2.10 Trans-well migration and invasion assays
The migration and invasion assays were performed in trans-well chambers
separteed by 8 µm pore size nitrocellulose filters (Corning). The membranes for the
invasion assay were coated with 1:2 diluted matrigel (BD Biosciences) solutions. The
cells were added in the top chamber in serum-free medium. Medium containing 10%
FBS served as a chemoattractant in the lower chamber. After incubation for 24 h, the
cells from the upper side of the membrane were removed by scraping with cotton swabs.
The cells on the lower side of the filter were fixed with methanol and then stained with
crystal violet and counted from 10 random fields. All the experiements have 3 replicates,
and repeated for three times.

2.11 In vivo xenograft tumorigenesis
10 million cells mixed with 0.2 ml Matrigel (BD Biosciences) were implanted in
the mammary fat pad of 4-6 week old non-pregnant female NSG mice (The Jackson
Laboratory). Three days prior to cell implantation, the mice were primed with s/c
estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research of America, Sarasota, FL).
Tumor growth was monitored weekly for 10 weeks. Tumor dimensions were measured
with Vernier calipers and tumor volume calculated as length x width x depth/2. At the
end of the experiment the tumors along with livers and lungs are taken out for fixation
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and further analyses. Mice were euthanized when control tumors reached 2 cm3 in
volume or showed signs of ill health, as per institutional IACUC guidelines.

2.12 Protein/DNA array based screen of DNA-binding activity of 345 transcription
factors
Protein/DNA arrays were used to simultaneously screen 345 transcription factors
for DNA-binding activity. This was carried out by using the protein/DNA combo-array kit
(cat. MA1215, Affymetrix, Santa Clara, CA). In brief, 4 µg of total nuclear protein
(prepared using the Panomics Nuclear Extraction Kit [Cat. AY2002, Affymetrix, Santa
Clara, CA]) were incubated with biotin-labeled DNA-binding probe mix provided by the
vendor (TranSignal Probe Mix) to allow the formation of complexes of transcription
factors (TFs) in the lysates with cognate DNAs in the probe mix. The protein-DNA
complexes were separated from free probes by electrophoresis in agarose gels. The
probes present in the complexes were eluted, denatured and hybridized to the
TranSignal membrane dotted with corresponding non-labeled probes, and the signals
were detected by chemi-luminescence.

2.13 Electrophoretic mobility shift assay (EMSA)
EMSA was carried out by using the EMSA kit (cat. 20148, Life Technologies,
Waltham, MA). The binding reactions were performed by adding 1 µg of nuclear extract
protein to a mixture containing 20 fmol of 5’- biotin end-labeled double-stranded DNA
probes in 20 µl of binding buffer. Competition reaction mixtures contained a 200-fold
molar excess of non-biotin-labeled oligonucleotides. The DNA-protein complexes were
separated on pre-cast native 7.5% polyacrylamide gels (cat. 456-1021, Bio-Rad,
Hercules, California) at 100 V and then transferred onto a PVDF membrane. The
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positions of the biotin end-labeled oligonucleotides were detected by a
chemiluminescent reaction according to the manufacturer’s instructions.

2.14 Cathepsin B (CTSB)/Cathepsin L (CTSL) activity assay
CTSB/L activity was performed using Magic Red CTSB/L Activity Kit (Cat. 937 &
941, Immunochemistry Technologies, Bloomington, MN) according to the manufacturer’s
protocol. Cells were seeded on coverslips and incubated with Magic Red CTSB
substrate for 1  h at 37  °C. The cells were washed with PBS, and fixed with
0.1% formaldehyde. The coverslips were mounted with medium containing DAPI
staining. Images were taken under fluorescence microscope. The fluorescence intensity
was further analyzed using Image J (NIH).

2.15 Extracellular matrix degradation assay
This assay was carried out using QCM™ Gelatin Invadopodia kit (Cat. ECM670,
EMD Millopore, Billerica, MA) according to the manufacturer’s protocol. FITC-labeled
gelatin was coated onto glass coverslips and crosslinked with 0.5% glutaraldehyde in
PBS for 30 minutes. Coated coverslips were then washed three times each with PBS
and 50 mM glycine in PBS. Cells were cultured for various time points to allow ECM
degradation, seen as focal loss of fluorescent signal (“holes”) in the labeled gelatin layer.
The fluorescence intensity was further analyzed using Image J (NIH).

2.16 Patient population and tissue microarrays
Tissue microarrays (TMAs) were prepared from formalin-fixed, paraffinembedded tissue specimens that include a series of primary operable (stage I and II)
breast carcinoma cases of age <70 presented consecutively between 1988 and 1998 at
the University of Nottingham Hospital Breast Unit with tumors of less than 5 cm diameter
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(100). This is a well-characterized series (900 cases) that includes clinical and
pathological data. These tissue arrays were provided by Dr. Emad Rakha, Pathologist at
University of Nottingham Hospital. The breast cancer specific survival (BCSS) is defined
as time (in months) from the date of primary surgery to the date of breast cancer-related
death. Distant metastasis free survival (DMFS) is defined as duration (in months) from
the date of primary surgery to the appearance of distant metastasis. The median age of
patients was 55 years (range 18–70 years) with a median BCSS of 129 months (range
4–243 months) and median time of DMFS of 114 months (range 5–241 months). Distant
recurrence occurred in 249 cases (31 %); 228 (29 %) patients died from breast cancer,
while 435 (56 %) patients were alive at the end of follow-up. Adjuvant systemic therapies
were provided according to the Nottingham Prognostic Index (NPI) group. Systemic
therapy was prescribed to the Excellent (NPI B 3.4) and Good (NPI 3.41–5.4) prognostic
Groups. The Moderate I group received hormonal therapy for ER+ tumors. The
Moderate II, Poor, and Very Poor Groups received hormone therapy for ER+ tumors and
cytotoxic therapy for ER- patients. Of the informative cases (n = 801) 360 have received
hormone therapy (45 %) while 201 cases received chemotherapy (25 %). None of the
patients received neoadjuvant therapy or anti-HER2 targeted therapy.

2.17 Scoring of TMA
Of the cores of the 900 breast cancer samples were analyzed as TMAs, sufficient
tissue was available to perform scoring in 803 cases and these form the basis of
analyses presented in this study. Normal controls included 25 normal human breast
tissue specimens. The tissue arrays were stained using immunohistochemistry with antiCHIP antibody as described previously (101).
Semi-quantitative assessment of staining intensity utilized a modified
histochemical score (H-score) that includes the intensity of staining and the percentage
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of stained cells. The intensity of staining was scored on a scale of 0 to 3 corresponding
to negative (0), weak (1), moderate (2), and strong (3) staining. Percentage of positive
cells was visually estimated. Multiplication of the two indices (intensity and percentage
positive cells) provided final scores that range from 0 to 300. The pattern of expression
was visually recorded as nuclear, cytoplasmic, or combined nuclear and cytoplasmic or
no nuclear/cytoplasmic staining. Any nuclear expression (>1) was considered positive,
while cytoplasmic expression was considered positive if it exceeded a cut-off of an Hscore of 110, which is based on histogram distribution of the cases as well as X-Tile
computer software analysis. All cases were scored by a trained pathologist without prior
knowledge of the clinic-pathological parameters or outcome data. The samples with
cytoplasmic staining were considered cytoplasmic positive regardless of nuclearnegativity or positivity; similarly nuclear positive cases included nuclear positive staining
regardless of cytoplasmic staining status.

2.18 Statistical analysis
Statistical analysis of tissue microarray IHC staining was performed using the
SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA). Optimal cut-offs for CHIP
expression were determined using the X-tile bioinformatics software (version 3.6.1,
2003–2005, Yale University, USA). Analysis of categorical variables was performed with
χ2 test. Survival curves were analyzed using the Kaplan–Meier method with significance
determined by the Log Rank test. Multivariate analysis was performed using the Cox
hazard analysis. Group comparison analysis was performed using student’s t test. A p
value (two-sided) of <0.05 was considered significant.
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3.1 Introduction
The ErbB family (ErbB1-4) of trans-membrane receptor tyrosine kinases (RTKs)
plays critical physiological roles (102-104). ErbB1 (EGFR) and ErbB2 (Her2/Neu) drive
oncogenesis in a number of human malignancies. ErbB2 overexpression, as a result of
gene amplification and/or increased transcription, drives oncogenesis in over a quarter
of human breast cancer patients (105){{109 Emde,A. 2012}} and also specifies poor
overall patient survival (105, 106). ErbB2 overexpression has been successfully
exploited for therapeutic targeting with humanized monoclonal antibodies (e.g.,
Trastuzumab, Pertuzumab) and more recently with small molecule kinase inhibitors (e.g.,
Lapatinib), resulting in significant improvement of treatment outcomes when added to
conventional chemo-radiotherapy (107, 108). De novo as well as rapidly acquired
resistance, however, has emerged as a major limitation to ErbB2-targetd therapy (109,
110). Newer avenues to promote more effective and durable responses to targeted
therapy of ErbB2-driven breast and others cancers are therefore urgently needed.
Overexpression of ErbB2, most often due to gene amplification, is a diagnostic
attribute of ErbB2-driven breast cancer and also a predictor of initial response to
targeted therapy. ErbB2 is a transmembrane (TM) glycoprotein synthesized in the ER,
and as such is subject to ER quality control, which ensures that the newly synthesized
proteins do not exit the ER until they are determined to be correctly folded and/or fully
assembled. Increase in the abundance of misfolded proteins triggers an unfolded protein
response, one arm of which carries out the dislocation of misfolded/unassembled TM
proteins into the cytosol for ubiquitin-dependent proteasomal degradation, a conserved
process of ER-associated degradation (ERAD) (111). A subset of ER-synthesized
proteins, which include the ErbB family member ErbB3, also undergo an ER “quantity”
control, which targets otherwise correctly folded proteins to ERAD to maintain their
physiological levels (112, 113). The folding of luminal domains of TM proteins is
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mediated by ER luminal Hsp90-family chaperones, such as Hsp94, while the folding of
cytoplasmic domains is mediated by the Hsp90-Hsc70 chaperone (Hsc70 will be used to
collectively refer to both constitutive and inducible members of Hsp70 family) (114). Both
of these pathways are hyperactive in ErbB2-overexpressing breast cancers, and appear
critical to maintain the oncogenic drive (111). Hsp90-Hsc70 chaperone complex is a
dual-purpose machine that promotes folding, but Hsc70 can also attain a prodegradation conformation (regulated by co-chaperones) to facilitate degradation of client
proteins whose mis-folding is sensed to be beyond restoration (106, 115). Studies of
cystic fibrosis trans-conductance regulator (CFTR) as a model TM protein illustrate this
process and have established that ER quality control of the cytoplasmic domains of TM
proteins requires the Hsp90-Hsc70 chaperone, with the associated ubiquitin ligase (E3)
CHIP functioning to promote a degradation state of Hsc70, leading to CFTR ERAD (62,
67, 77).
Newly-synthesized RTKs, including EGFR and ErbB2, associate with Hsp90Hsc70 on the ER, and inhibition of Hsp90 with geldanamycin (GA) or its analogues (such
as 17AAG) promotes rapid RTK degradation, indicating a requirement for Hsp90-Hsp70
complex to promote folding of newly synthesized RTKs (116-118). Distinct from other
RTKs, however, ErbB2 remains Hsp90-associated even after its exit from the ER. As
others and our laboratory have shown, the inhibition of Hsp90 promotes rapid
ubiquitination and degradation of mature ErbB2 protein (74, 75, 118). Notably, Hsp90
inhibitors exhibit selectively higher antitumor effects against ErbB2-overexpressing
breast cancer cells and these effects are synergistic with ErbB2-targeted therapeutics,
trastuzumab or lapatinib (119). Thus, increased Hsp90-Hsc70 chaperone function in
ErbB2-overexpressing breast cancers is a co-driver of oncogenesis and a therapeutic
target. Indeed, the Hsp90 inhibitor and trastuzumab combination is currently undergoing
clinical evaluation in breast cancer (www.clinicaltrials.gov) (120). Understanding how
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Hsp90-Hsc70 complex protects ErbB2 and how Hsp90 inhibitors promote its degradation
are therefore critical biological and clinically-relevant questions.
Since treatment of ErbB2+ breast cancer cells with Hsp90 inhibitors promotes
rapid ubiquitination and proteasome-dependent degradation (117), identification of the
ubiquitin ligase (E3) CHIP (C-terminus of Hsc70 Interacting Protein) as a binding partner
and inhibitor of the folding function of Hsc70 (65) suggested that it may serve as
mediator of Hsp90 inhibitor-induced ErbB2 degradation. Consistent with this idea,
others and our laboratory observed that overexpression of CHIP in ErbB2overexpressing breast cancer cell lines enhanced the GA- or 17AAG-induced
ubiquitination and degradation of ErbB2 (74, 75). However, ErbB2 degradation upon
Hsp90 inhibition was unaffected in CHIP-null mouse embryonic fibroblasts (MEFs) (74)
and upon CHIP shRNA KD in distinct ErbB2-overexpressing breast cancer cell
lines(Figure 3.1). Thus, these studies clearly established that CHIP was not a mediator
of acute degradation of mature ErbB2 (which is predominantly at the cell surface) upon
Hsp90 inhibition. However, despite a lack of involvement of CHIP in ErbB2 degradation
induced by Hsp90 inhibitors, several recent lines of evidence support a critical
involvement of CHIP in the regulation of ErbB2-driven oncogenesis. In this chapter, we
demonstrate that newly synthesized ErbB2 is a direct target of CHIP-mediated
ubiquitination and degradation, through a modified ERAD pathway.

3.2 CHIP regulates cell surface ErbB2
To examine the molecular mechanisms underlying CHIP-mediated ErbB2
degradation, we first developed stable CHIP knock-down (KD) ErbB2+ breast cancer
cells. We observed that cell surface ErbB2 level increased in the 21MT1 CHIP KD cells
comparing with 21MT1 control cells when analyzed by FACS analysis (Figure 3.2A, left
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panel). This result was consistent with higher surface ErbB2 staining in CHIP KD cells
analyzed by immunofluorescence imaging (Figure 3.1 B).
Next, we constructed stable ErbB2+ breast cancer cells with Myc-tagged CHIP
overexpression to check the impact on ErbB2 levels. As we expected, surface ErbB2
level was decreased in CHIP overexpressing cells comparing with control cells (Figure
3.2A, right panel). The CHIP level in ErbB2+ cells was verified by western blotting
(Figure 3.1B).
As CHIP is a E3 ubiquitin ligase, we asked if ErbB2 was a direct target of CHIP
without any stimuli such as Hsp90 inhibition. Previous reports demonstrated that CHIP
could regulate the protein quality control both in the ER, with CFTR as a well-studied
example, and in the cytoplasm (67). We therefore asked if CHIP plays an important role
in ErbB2 quality/quantity control since overexpression creates opportunities for
increased mis-folding of the newly synthesized ErbB2 proteins.

3.3 CHIP ubiquitinates ErbB2 for degradation
To confirm the surface ErbB2 level change was due to CHIP involvement in
ErbB2 ubiquitination, we performed immuneprecipitation assays in CHIP-overexpressing
vs. parental ErbB2+ BT474 breast cancer cells. CHIP overexpression increased basal
ErbB2 ubiquitination even without proteasome inhibitor bortezomib treatment while
control cells did not show any ubiquitination signals. Proteasome inhibition further
elevated ubiquitination of ErbB2 in CHIP overexpressing cells compared to control cells
(Figure 3.3), suggesting that proteasome degradation was an essential pathway for
ErbB2 degradation. These data demonstrated that CHIP itself functions as an E3
ubiquitin ligase targeting ErbB2 for proteasome degradation in the absence of Hsp90
inhibition. However, the total ErbB2 level was not changed dramatically when CHIP was
overexpressed in ErbB2+ cells. One possible explanation was that in these ErbB2

	
  

37

overexpressing cells ectopic-CHIP expression was not high enough to clear all the
ErbB2 protein and that CHIP only targeted a small pool of ErbB2. Given our results
described below on CHIP localization, we reason that it is the newly-synthesized pool of
ErbB2 that is targeted by CHIP.

3.4 CHIP destabilizes immature form of ErbB2
Since we showed that alterations in CHIP expression predominantly impacted
the cell surface ErbB2 expression, we undertook analyses of the impact of CHIP
expression on ErbB2 during its maturation process. We performed 35Smethionine/cysteine-labeling pulse-chase experiments to investigate if CHIP
overexpression could affect the stability and maturation of newly synthesized ErbB2. As
shown in Figure 3.4A, two bands of ErbB2 appeared after radiolabeled pulse and chase.
The low-molecular-weight immature form (precursor) appears after pulse-labeling, while
the higher molecular-weight mature form appears after chase and reflects the post-ER
glycosylated form that is eventually transported to the cell surface (74). CHIPoverexpressing 21MT1 cells had a similar maturation pattern as the control cells;
however, the intensity of the mature ErbB2 form in CHIP overexpressing 21M1 cells was
reduced relative to the intensity of the initial precursor form compared to the pattern in
control 21MT1 cells (Figure 3.4B). In the control 21MT1 cells, almost 70% of the
immature form converted to the higher molecular weight form, consistent with a
proportion of the newly-synthesized ErbB2 being degraded through ERAD as part of the
protein quality control. In CHIP-overexpressing 21MT1 cells only 50% of immature form
converted into the higher molecular weight form, consistent with a larger proportion of
newly-synthesized ErbB2 undergoing ERAD. These results provide a plausible
explanation for reduced export of ErbB2 to the cell surface in CHIP-overexpressing cells.
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Next, to test whether CHIP promoted the instability of the immature form of

ErbB2, we performed 35S-methione/cysteine pulse-chase experiments without or with
brefeldin A (BfA), an inhibitor of the transport of newly-synthesized membrane proteins
from ER to Golgi apparatus. Under BfA treatment, newly-synthesized ErbB2 would be
expected to remain in an immature form in the ER instead of maturing in the Golgi for
transport to the cell surface. As expected, BfA treatment for 4 hours efficiently blocked
the appearance of the mature form of newly-synthesized ErbB2, as there was no signal
of high-molecular-weight band detected (Figure 3.4C). Indeed, we observed that CHIP
overexpressing 21MT1 cells showed a faster loss of the immature radiolabeled ErbB2
compared to the kinetics of loss f signal in control 21MT1 cells (Figure 3.4D). This result
further supports the conclusion that CHIP targets the immature form of ErbB2 for
degradation at the ER. Thus, extending previous findings (68), our results show that
newly-synthesized ErbB2 targeted for ERAD by CHIP.

3.5 CHIP overexpression promotes intracellular retention of ErbB2 in ER and Golgi
Since CHIP overexpression was observed to promote the destabilization of ERlocalized ErbB2, likely reflecting its targeting to ERAD pathway, we hypothesized that
CHIP may function at the ER or Golgi to prevent incorrectly-folded, newly-synthesized
ErbB2 from being exported to the cell surface and preparing it for ERAD. To further
explore this idea, we performed immunofluorescence imaging studies to asses the
localization of ErbB2 in CHIP-overexpressing vs. parental SKBR3 cells. As shown in
Figure 3.5, ectopically-overexpressed CHIP-GFP in ErbB2+ SKBR3 cells colocalized
with markers of ER and Golgi (Figure 3.5A, calnexin staining represents ER; Figure 3.5B,
GM130 staining represents cis-Golgi), suggesting that CHIP can function in both ER and
Golgi apparatus. Importantly, cells with ectopic CHIP-GFP overexpression exhibited
substantially reduced levels of surface ErbB2 staining, consistent with our conclusion
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that CHIP function at ER and Golgi negatively regulates ErbB2 transport to the cell
surface.
We further looked at the ErbB2 staining in stably CHIP-overexpressing vs.
control ErbB2-overexpressing 21MT1 cells. In CHIP overexpressing 21MT1 cells, we
observed increased intracellular ErbB2 while no intracellular ErbB2 was seen in control
cells (Figure 3.6 and Figure 3.7). Under these conditions, the intracellular ErbB2 did not
co-localize with an ER marker calnexin (Figure 3.6); instead, it co-localized with a Golgi
apparatus marker GM130 (Figure 3.7A). To further validate the Golgi localization of
intracellular ErbB2, we transfected SKBR3 cells with a plasmid coding for a Golgilocalized pmTurquoise fluorescent probe (from Addgene). Ectopic pmTurquoise Golgi
marker also co-localized with intracellular ErbB2 in CHIP-overexpressing cells while no
co-localization was observed in control cells (Figure 3.7B). The quantification of Golgi
and ErbB2 co-localized cells confirmed that intracellular ErbB2 were stuck in the Golgi in
most of the CHIP overexpressing ErbB2+ cells (Figure 3.7C).
The classical ‘ERAD’ is thought to take place at the ER organelle (6). Since we
observed the CHIP-mediated destabilization of immature ErbB2 in stably CHIPoverexpressing cells, yet intracellular ErbB2 was only seen in Golgi in these cells, the
CHIP-dependent control on newly synthesized ErbB2 does not appear to simply involve
retention in the ER followed by ERAD. We speculate that partially unfolded ErbB2,
apparently in association with Hsp90, is allowed to progress to the Golgi apparatus.
However, association of CHIP with molecular chaperones is likely to prevent its further
transport and may promote retro-transport to ER for degradation. Notably,
overexpressed ErbB2 is unique among its family members to require Hsp90 for its
stability in its mature form, including that present on the cell surface. In contrast, other
RTKs, such as EGFR, require Hsp90 only in their newly-synthesized forms (29). In a
previous study from our laboratory(75), elevated interaction of ErbB2 and Hsp70 was
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found upon U-box mutant CHIP H260Q expression, but ErbB2/Hsp90 complex did not
disassociate when cells were treated with an Hsp90 inhibitor 17AAG, a result in contrast
to results with parental cells or cells expressing wildtype CHIP. We reason that CHIP
acts as a negative co-chaperone for Hsp90/Hsc70 (65) and promotes the release of
Hsp90/Hsc70 from ErbB2, thereby exposing the inherent hydrophobic sequences
previously identified in ErbB2 to be required for Hsp90 chaperone (118). It is likely that
this switch leads to newly-synthesized ErbB2 being sensed as an unfolded protein,
promoting its retention in the Golgi/ER and eventual targeting for ERAD. To assess if
this model is likely, we carried out IP/Western blotting analysis of ErbB2 association with
Hsp90 and Hsc70, upon CHIP KD. As shown in Figure 3.8, CHIP KD increased the
interactions of ErbB2 with Hsp90 and Hsp70. Thus, tumor-associated loss of CHIP can
be viewed as an adaptive mechanism to relieve ErbB2 of a bottleneck on its transit to
the cell surface in association with Hsp90.

3.6 Reduced expression of CHIP promotes ER stress
The needs for protein quality control are elevated in cancer cells as their higher
metabolic demands create elevated ROS levels and increased protein synthesis creates
additional protein unfolding (121). Since CHIP is known to serve as a key regulator of
protein quality control (65, 70), it is reasonable to anticipate that lower levels of CHIP will
promote the accumulation of unfolded proteins and elevate ER stress. To test this idea
experimentally, we used the treatment with proteasome inhibitor bortezomib, a clinicallyused drug known to induce ER stress (122-124). We treated 21MT1 control cells and
their CHIP KD derivative cells with bortezomib for various time points and analyzed the
expression of ER stress marker CHOP (C/EBP homologous protein) were examined by
western blotting. As shown in Figure 3.9, CHOP levels were increased in control cells
upon bortezomib treatment but this was seen primarily at later time point (8 hours); in
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contrast, basal CHOP levels were elevated in CHIP KD cells copared to control cells and
bortezomib treatment led to an earlier increase in CHOP levels, indicating that CHIP is
required to mitigate ER stress and that reduced levels of CHIP, as are now known to
occur in tumors such as ErbB2+ breast cancer (124), would be expected to increase the
basal levels of ER stress.
A high ER stress level is known to trigger the unfolded protein response (UPR)
(125). Depending on the duration and degree of ER stress, the UPR could provide either
survival signals by activating adaptive and anti-apoptotic pathways, or death signals by
inducing cell death programs. The former is thought to occur in tumor cells which
activate the UPR gradually and contributes to their ability to survive and exhibit other
oncogenic traits under hostile environments such as tissue hypoxia and lack of nutrients
(125). Therefore, acute elevation of ER stress or repression of the adaptive UPR
mechanisms pharmacologically has been proposed as a means to elevate ER stress to
levels that could produce cell growth inhibition or death, and hence produce a beneficial
therapeutic effects against cancer (126). We tested whether lower expression of CHIP in
tumor cells could indeed sensitize them to acute elevation of ER stress and lead to an
anti-tumor effect using anchorage-independent growth in soft agar as well as 2D cell
proliferation assays to assess the effects of bortezomib. As shown in Figure 3.10A, CHIP
KD SKBR3 cells had elevated colony formation compared to control cells. Treatment
with bortezomib led to a dose-dependent inhibition of colony formation. However, when
we compared the efficiency of colony formation (Figure 3.10B), boretomib treatment led
to a a dramatic decrease in CHIP KD cells as compared with control SKBR3 cells. In 2D
proliferation assay, the IC50 for bortezomib in CHIP KD cells was 10+1.2nM, compared
to 15+ 1.3nM in control cells (Figure 3.10C), consistent with the increased sensitivity of
tumor cells with increased ER stress due to loss of CHIP expression to acute
pharmacologic elevation of ER stress.
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3.7 ER stress inducer synergistically inhibit ErbB2+ cells with Trastuzumab
Trastuzumab (Herceptin, from Genentech, part of Roche) is a standard targeted
therapeutic antibody for ErbB2+ breast cancer since 1998. We therefore investigated if
elevated ER induction with bortezomib could have a synergistic or additive effect with
Trastuzumab ErbB2+ breast cancer cells. We performed proliferation assays on BT474
cells by treating with bortezomib alone, Trastuzumab alone, or a combination of both. As
shown in Figure 3.11, BT474 cells showed a dose dependent growth inhibition upon
bortezomib or Trastuzumab alone treatment. Analysis of the Combination Index of the
effects of combined bortezomib and Trastuzumab treatment as an indicator of their
interaction indicated that bortezomib and trasuzumab could synergistically inhibit BT474
cell growth (combination indices between between 0 and 1). These results further
establish that CHIP is a key regulator of oncogenic traits and therapeutic sensitivity of
tumor cells, and the results described here could form the basis of future efforts to target
CHIP-low breast ErbB2+ cancers with a combination of ER stress inducers such as
bortezomib together with Trastuzumab to produce a therapeutic improvement for
patients with ErbB2+ breast cancer.

3.8 Discussion
In this chapter, we established a novel role of CHIP in regulating ErbB2 through a
modified ERAD pathway. Our results suggest that CHIP-dependent alterations in the
association of ErbB2 with molecular chaperones are an important mechanism to
promote the Golgi to surface transport of newly-synthesized ErbB2 in ErbB2overexpressing breast cancer cells. Thus, loss of CHIP in a majority of EbB2+ breast
cancers may accentuate oncogenesis in part by ensuring that HSP90 remains
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associated with ErbB2 and allows this complex to exit ER/Golgi for transport to cell
surface where it functions to promote oncogenesis.
As discussed in the introduction, Hsp90-Hsc70 chaperone monitors the folding
state of cytoplasmic domains of TM proteins (20, 29). CHIP, as a negative cochaperone, promotes the pro-degradation state of the Hsp90-Hsc70 chaperone. Studies
of model TM proteins, such as CFTR, have demonstrated that misfolding of cytoplasmic
domains triggers Hsp90-Hsc70 chaperone-dependent ERAD (67, 77). Overexpressed
ErbB2, which lacks any mutations, is persistently bound to Hsp90-Hsc70 chaperone
even in its mature state through a unique hydrophobic patch on ErbB2 (118). Inhibition
of this association (by Hsp90 inhibitors) leads to rapid degradation of ErbB2 (74, 75).
When the aforementioned hydrophobic patch was rendered EGFR-like, the mature form
of this mutant ErbB2 is insensitive to Hsp90 inhibitors; under these conditions, Hsp90Hsc70 still interacted with the cytoplasmic region, but through another undefined region,
and Hsp90 inhibition only destabilized the newly synthesized form, indicating that
Hsp90-Hsc70 chaperone was separately needed to stabilize the cytoplasmic domain of
newly synthesized ErbB2. As shown in this study, CHIP in ErbB2-driven breast cancer
played the essential role as an enforcer of ErbB2 ERAD. As CHIP-dependent ERAD was
enforced on immature ERbB2 and was accentuated by the retention of this form in the
ER using brefeldin-A, it would be consistent with ER quality control roles assigned for
CHIP in the context of mutant CFTR. An example of the ER “quantity” control has been
presented in which the ER-localized ubiquitin ligase Nrdp1 enforces the ERAD of ErbB3
to control its surface levels (112, 113). It is therefore plausible CHIP-dependent control
of the ERAD of ErbB2 could also function as a “quantity” control rather than “quality”
control since ErbB2 is transported to the cell surface in a chaperone-associated form
and is functional in this form.
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It should be noted that acutely overexpressed CHIP co-localized with the ER and

Golgi in ErbB2-overexpressing breast cancer cells (Figure 3.5), as previously described
previously in other cells (89). It is therefore plausible that CHIP may function at both
organelles during the ER quality/quantity control newly-synthesized transmembrane
proteins such as ErbB2. R, However, stably overexpressed CHIP localized primarily in
the Golgi and not the ER in ErbB2-overexpressing cells. Since our results with pulsechase labeling clearly show that CHIP regulates the conversion of newly sysnthesized
immature to mature form of ErbB2 and that inhibition of ER to Golgi transport of ErbB2
exposed immature ErbB2 to CHIP-dependent degradation (Figure 3.4), we suggest that
CHIP function towards ErbB2 and potentially other transmembrane proteins, is more
complex than simply ERAD. We speculate that CHIP association with molecular
chaperones bound to transmembrane proteins such as ErbB2 promotes ERAD and in
addition can expose the targeted proteins for degradation even in non-ER compartments
such as Golgi but that such processes may be slower compared to ERAD (thus
accounting for a pool of CHIP and ErbB2 being seen in the Golgi but not in the ER in
stably CHIP-overexpressing ErbB2+ breast cancer cells). This idea is consistent with
recent results in which mutant CFTR was shown to undergo an ERAD-like degradation
dependent in part on CHIP even at the cell surface (127). It is also possible that CHIPdependent ubiquitination of either molecular chaperones (128) or transmembrane
proteins such as ErbB2 (74, 75), promotes the retrograde transport from Golgi to ER
where the marked proteins are then eliminated by ERAD. Notably, CPY protein has
been shown to be retro-transported from Golgi to ER for ERAD (129).
Demonstration of CHIP as an enforcer of ErbB2 ERAD would allow future studies
to test therapeutic options that target components of ERAD and the linked unfolded
protein stress and UPR response pathways. Recent studies have shown that the
proteasome inhibitor Bortezomib, which was approved by the FDA for treating multiple

	
  
myeloma (130), has a very potent inhibitory effect on breast cancer cell lines, and clinical
trials to test Bortezomib in breast cancer patients are ongoing (122, 123). Our in vitro
proliferation data suggests that a combination of Bortezomib and Trastuzumab
specifically in ErbB2+ patients that show reduced CHIP expression could produce a
therapeutic improvement.
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Figure 3.1 CHIP is not required for Hsp90 inhibition induced ErbB2 degradation
(A). 21MT1 control and CHIP KD cells were treated with 17AAG for different time
points. Western blot analysis of cell lysate for ErbB2 and CHIP, Hsc70 is the loading
control. (B). SKBR3 control and CHIP KD cells were seed on cover slips and treated
with 17AAG for 8 hours, cells then were fixed and stained with anti-ErbB2 antibody
followed by secondary fluorescent conjugate. Cover slips were mounted with DAPI
staining and further taken images under confocal microscopy.
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Figure 3.2 CHIP regulates cell surface ErbB2
(A). 21MT1 cell surfaceErbB2 level is determined by FACS analysis. Knockdown
of CHIP increased cell surface ErbB2, overexpression of CHIP further decreased cell
surface ErbB2. Data represent mean + S.D., n=6 (B). Western blot analysis of 21MT1
cell lysate for CHIP, Hsc70 is the loading control.
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Figure 3.3 CHIP elevates basal ubiquitinates of ErbB2
BT474 cells were seed in 10cm dishes and incubated with or without treatment of
proteasome inhibitor bortezomib for 4 hours. Cleared lysates from cells harvested were
quantified by BCA assay. ErbB2 was immuoprecipitated by using trastuzumab (5ug/ml),
ubiquitin and ErbB2 signals were detected in immuoprecipitates (upper panel) and ErB2,
and CHIP signals were detected in whole cell lysates (lower panel).
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Figure 3.4 Overexpression of CHIP down regulates newly synthesized ErbB2
(A) 21MT1 cells were pulse-labeled for 20 min with [35S] methionine-cysteine and
were then chased with excess unlabeled methionine-cysteine medium. Cleared lysates
from cells harvested at the indicated times were immunoprecipitated with anti-ErbB2
antibodies and were analyzed by autoradiography. (B) Quantification of ErbB2 signal in
A. (C) 21MT1 cells were pulse-labeled for 20 min with [35S] methionine-cysteine and
were then chased with excess unlabeled methionine-cysteine medium with Brefeldin A
treatment. Cleared lysates from cells harvested at the indicated times were
immunoprecipitated with anti-ErbB2 antibodies and were analyzed by autoradiography.
(D) Quantification of ErbB2 signal in C.

	
  

53

	
  

54

Figure 3.5 CHIP co-localized with ER and Golgi apparatus
(A) SKBR3 cells were seed on cover slips and transiently transfected with CHIPGFP vector, cells then were fixed and stained with anti-ErbB2 and anti-calnexin antibody
followed by secondary fluorescent conjugate. Cover slips were mounted with DAPI
staining and further taken images under confocal microscopy. (B) SKBR3 cells were
seed on cover slips and transiently transfected with CHIP-GFP vector, cells then were
fixed and stained with anti-ErbB2 and anti-GM130 antibody followed by secondary
fluorescent conjugate. Cover slips were mounted with DAPI staining and further taken
images under confocal microscopy.
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Figure 3.6 ErbB2 does not co-localize with ER in CHIP overexpressing ErbB2+
cells
21MT1 cells were seed on cover slips, then fixed and stained with anti-ErbB2
and anti-calnexin antibody followed by secondary fluorescent conjugate. Cover slips
were mounted with DAPI staining and further taken images under confocal microscopy.
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Figure 3.7 ErbB2 co-localized with Golgi in CHIP overexpressing ErbB2+ cells
(A) 21MT1 cells were seed on cover slips, then fixed and stained with anti-ErbB2
and anti-GM130 antibody followed by secondary fluorescent conjugate. Cover slips were
mounted with DAPI staining and further taken images under confocal microscopy. (B)
SKBR3 cells were seed on cover slips and transiently transfected with pmTurquoiseGolgi vector, cells then were fixed and stained with anti-ErbB2 antibody followed by
secondary fluorescent conjugate. Cover slips were mounted with DAPI staining and
further taken images under confocal microscopy. (C) Quantification of Golgi and ErbB2
co-localized cells in A & B.
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Figure 3.8 Loss of CHIP elevates interaction between ErbB2 and Hsp90/Hsp70
21MT1 Cells were seed in 10cm dishes and incubated with or without treatment
of Hsp90 inhibitor 17AAG for 4 hours. Cleared lysates from cells harvested were
quantified by BCA assay. ErbB2 was immuoprecipitated by using trastuzumab (5ug/ml),
Hsp90, Hsp70 and ErbB2 signals were both detected in immuoprecipitants (right panel)
in whole cell lysates (left panel).
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Figure 3.9 Loss of CHIP induces ER stress
21MT1 Cells were seed in six well plates and incubated with or without treatment
of proteasome inhibitor Bortezomib for different time points. Cleared lysates from cells
harvested were quantified by BCA assay. ErbB2, CHOP and CHIP signals were
detected from western blotting, Hsc70 served as loading control.
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Figure 3.10 Loss of CHIP sensitizes growth inhibition by stress inducer in ErbB2+
cells
(A) SKBR3 cells were seed in soft agar plates (0.6% bottom, 0.35% upper) with
the treatment of proteasome inhibitor Bortezomib at different concentrations and
incubated for 3 weeks. Colonies were stained, imaged and analyzed under microscope.
Data represent mean + S.D., n=3. (B) The colony numbers in A were normalized to the
untreated group of control cells. (C) SKBR3 cells were seed in 96 well plates, followed
by the treatment of proteasome inhibitor Bortezomib at different concentrations for 5
days. Plates were stained with MTT and read under plate reader. IC50 was calculated
by Prism software.
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Figure 3.11 Trastuzumab and bortezomib synergistically inhibit BT474
proliferation
BT474 cells were seed in 96 well plates, followed by the treatment of
trastuzumab alone (A), Bortezomib and the two combinations (B) at different
concentrations for 5 days. Plates were stained with MTT and read under plate reader.
Data represent mean + S.D., n=3 (C) Combination index was calculated by the software
of Prism.
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Chapter 4: Loss of CHIP in breast cancer unleashes a program
of tumor invasion and metastasis mediated by the transcription
factor MZF1 and its targets, cathepsins
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4.1 Introduction
ErbB2 overexpression, as a result of gene amplification and/or increased
transcription, drives oncogenesis in about 20%-25% of human breast cancer patients
and specifies poor overall survival (131). ErbB2 overexpression and mutations also
drive smaller subsets of other cancers, such as aero-digestive and ovarian cancers.
Targeting of overexpressed ErbB2 with humanized monoclonal antibodies (e.g.,
Trastuzumab, Pertuzumab), and recently with small molecule kinase inhibitors (e.g.,
Lapatinib), in combination with conventional chemo-radiotherapy has led to significant
improvements in treatment (107, 108). All treated patients however will eventually
develop resistance, through de novo or acquired mechanisms, leading to eventual
disease progression and death due to metastatic disease (109, 110). Current antibodybased therapeutics are also ineffective against brain metastases due to their inability to
cross the blood-brain barrier (108). Newer avenues whose targeting could improve the
existing ErbB2-targeted therapies to impart more effective and lasting responses are
urgently needed.
While overexpressed ErbB2 is the driver of oncogenesis in ErbB2+ tumors,
substantial rewiring of biochemical pathways in tumor cells, together with alterations in
tumor microenvironment are also essential (132). One such pathway is mediated by the
Hsp90-Hsc70 molecular chaperone complex, which is essential to facilitate the folding of
newly synthesized proteins and assembly of multi-subunit protein complexes (133). A
number of signaling proteins, including ErbB2 itself, perpetually remain Hsp90associated to maintain their mature functional states (134). Specific inhibition of Hsp90
ATPase activity (e.g., with 17AAG) rapidly destabilizes ErbB2, and results in tumor cell
killing (119, 135). As our laboratory has shown (119, 135), Hsp90 inhibitors synergize
with ErbB2-targted therapeutics and such combinations are now under clinical
development although beset with toxicity (120).
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At the molecular level, ErbB2+ breast cancers express higher levels and a more

active conformation of Hsp90 (136, 137). The Hsp90-Hsc70 chaperone complex is a
dual-purpose machine that promotes folding but its Hsc70 component can also attain a
pro-degradation conformation (133). These transitions are regulated by co-chaperones
that interact with Hsp90/Hsc70.	
   The positive co-chaperone Hop and negative cochaperone CHIP (C-terminus of Hsc70-interacting protein; also called STUB1) interact
with the C-termini of Hsp90 and Hsc70, and mediate an on-off switch (138, 139).
Elevated phosphorylation near the C-termini of Hsp90 and Hsc70 was shown to
enhance Hop interaction and reduce CHIP interaction, providing one mechanism for
upregulation of the active Hsp90-Hsc70 form in breast cancer (26). Loss of CHIP
expression has now emerged as another mechanism
CHIP is a U-box-containing ubiquitin ligase (E3) that interacts with Hsp90 and
Hsc70 through its TPR domains. The co-chaperone function of CHIP is essential for
protein quality control, and a substantial number of cellular proteins have been identified
as binding partners and targets of CHIP E3 activity(138, 138, 139, 139, 140, 140). These
include ErbB2 itself, as others and we have demonstrated (74, 75), and is further
demonstrated by studies presented in Chapter 3 of this thesis. Recent clinical studies
support a tumor suppressor function of CHIP in ErbB2+ breast cancers. Two studies of
smaller breast cancer cohorts showed that CHIP mRNA or protein expression was
reduced in cancer tissues of a majority of ErbB2+ and triple-negative patients, and loss
of CHIP expression predicted poor patient survival (83, 92). However, another study
came to an opposite conclusion (93). In one study, it was shown that CHIP depletion in
ER+ MCF7 cells upregulated the expression of ER coactivator SRC3, which was found
to be a CHIP target (83). The significance of this finding to ErbB2+ and triple-negative
breast cancers, a majority of which does not express ER, is unclear and oncogenesisrelevant targets of CHIP in these breast cancer subtypes remain unknown.
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Here, we undertook an extensive clinical-pathological study using a cohort (>800

patients) of extensively annotated breast cancer tissues (100). Further, we utilized
protein/DNA array to identify a novel pathway, mediated by the transcription factor MZF1
and impinging on matrix degrading enzymes cathepsin B and L, that is regulated by
CHIP and whose deregulation as a result of loss of CHIP expression contributes to
ErbB2+ breast cancer progression. We further show that targeting this pathway could
serve as a potential therapeutic avenue for breast cancer.

4.2 Decreased nuclear CHIP expression correlates with clinical characteristics and
a poorer survival in breast cancer patients
That CHIP may serve as a tumor suppressor is supported by reports in different
solid tumors that show loss of CHIP expression with tumor progression. In our study,
immunohistochmical staining of CHIP in tissue microarrays (TMAs) from about 956
breast cancer patients revealed two distinct patterns: cytoplasmic and nuclear staining
(Figure 4.1A). The Kaplan-Meier analysis revealed that low nuclear staining pattern was
significantly correlated with poorer breast cancer specific survival of all the breast cancer
patients while cytoplasmic CHIP staining was not predictive (Nuclear CHIP p=0.003 Vs.
cytoplasmic CHIP p=0.469, Figure 4.1B). As shown in Table 4.1 lower nuclear CHIP
expression in the cancerous tissues was also significantly correlated with clinicpathological feathers of tumor progression, such as higher tumor size, tumor grade,
pleomorphism and mitosis status. However, the cytoplasmic CHIP expression was not
significantly correlated with these features (Table 4.1). Loss of nuclear CHIP expression
also showed a significant correlation with high levels of various biochemical markers of
tumor progression and metastasis (Table 4.2), such as reduced staining for hormone
receptors ER and PR, altered cytokeratins (CK 18, CK19), increased early epithelialmesenchymal transition markers (N-cadherin, P-cadherin) and EGFR family proteins
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(EGFR, ErbB2, ErbB4). However, none of those markers correlated with cytoplasmic
CHIP expression except CK 18 (p=0.001) and ErbB2 (p=0.016) (Table 4.3). Thus, our
large TMA analysis confirmed previous findings that low CHIP expression is found in
larger subsets (about 2/3rd) of ErbB2+ and triple-negative breast cancer patients and a
smaller subset (1/3rd) of ER+ patients, but more importantly demonstrated that it is the
loss of nuclear staining of CHIP that provides a marker of poor disease-free survival and
tumor progression. These latter findings provided a basis for further studies to
demonstrate a mechanistic basis of how loss of nuclear CHIP may contribute to breast
cancer oncogenesis. Given the overall focus of this thesis on ErbB2-driven oncogenesis
as a model to investigate the tumor suppressor function of CHIP, we used ErbB2+
breast cancer cell lines as a primary model. However, key findings related to new
mechanistic insights were confirmed in limited experiments in triple-negative and ER+
breast cancer cell line models.

4.3 CHIP suppresses ErbB2+ breast cancer cell growth and tumor formation both
in vitro and in vivo
Given our TMA IHC results and previous studies indicating lower CHIP
expression in ErbB2+ and triple-negative breast cancers, we examined the mRNA and
protein levels of CHIP in a panel of human breast cancer cell lines that included
examples of all three major subsets as well as immortal mammary epithelial cell line
controls. The CHIP expression levels (both mRNA and protein level) were found to be
lower in ErbB2+ and in triple negative cells compared to normal mammary epithelial cell
lines and ER+ breast cancer cell lines (Figure 4.1C and 4.1D); analyses of ER+ and
triple-negative cell lines are consistent with a previous report (83) but our analyses show
clearly that ErbB2+ breast cancer cell lines recapitulate the lower expression of CHIP
seen in this subset of breast cancer in patient samples.
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We then asked whether the tumorigenic traits of ErbB2-overexpressing breast

cancer cell lines were dependent on the relaxed protein quality control expected in these
cells as a result of reduced levels of CHIP expression. This was clearly suggested by our
experiments (Chapter 3) in which the low CHIP levels in ErbB2+ breats cancer lines
were further reduced by CHIP KD, resulting in increased ErbB2 surface expression. For
this purpose, we engineered three ErbB2+ cell lines to stably overexpress CHIP
(CHIPOE , Figure 4.1E)
We used ErbB2-overexpressing 21MT1 cell line CHIP-hi/low cell pair to
investigate the role of CHIP in proliferation, anchorage-independent cell growth and
invasiveness,, important in vitro traits associated with tumor progression. While no
significant difference in proliferation was observed in a single passage, consistent with a
similar result upon CHIP overexpression in triple-negative breast cancer cell line MDAMB231 published previously (83), our analysis of cumulative cell proliferation over
multiple passages revealed that CHIPOE cells proliferated modestly but significantly lower
compared to control cells (Figure 4.3A). In a more stringent assay of proliferation under
anchorage-independent conditions in soft agar, CHIPOE cells exhibited a significantly
lower number of colonies compared to control cells (Figure 4.3B), indicating the CHIP
overexpression decreased anchorage-dependent cell growth. We next performed transwell migration and invasion assays using serum growth factors to provide a
chemoattractant gradient. These analyses demonstrated that CHIPOE cells show a
significantly reduced ability to migrate in trans-well chambers (Figure 4.3C) and a
significantly reduced invasion through Matrigel, as shown by the number of cells that
penetrated the Matrigel-coated membrane (Figure 4.3D).
Nude mice were orthotopically implanted in the mammary fat pad with BT474
CHIPOE and control cells (6 mice per group). The CHIP-overexpressing BT474 cells
formed significantly smaller tumors compared those formed by control cells (Figure 4.2A
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and 4.2B). Exogenous CHIP overexpression in tumors was confirmed by western
blotting (Figure 4.2C). Histologic examination revealed that, compared with control cells,
CHIPOE tumor cells had a lower degree of nuclear atypical and a lower mitotic index
(Figure 4.2D). In addition, immunostaining of the proliferative marker Ki67 demonstrated
that the ratio of proliferative cells was lower in CHIPOE tumors (Figure 4.2E and 4.2F).
However, immunostaining of the apoptotic marker cleaved-caspase 3 did not show any
significant difference between control and CHIPOE tumors (Figure 4.2E and 4.2G),
suggesting that the impact of CHIP overexpression is primarily cytostatic.
The results of these assays indicated that the oncogenic potential of ErbB2+ cells
was significantly decreased by CHIP overexpression and supports the idea that loss of
CHIP expression in ErbB2+ breast tumors promotes tumor progression as suggested by
our clinical-pathological analyses.

4.4 Identification of potential nuclear targets of CHIP using a screen of cognate
DNA-binding activities of nuclear transcription factors
Given our results with breast cancer tissue IHC analyses, which highlighted the
loss of nuclear but not cytoplasmic CHIP expression as a predictor of tumor progression
and poor patient outcomes, we reasoned that targets of CHIP relevant to its tumor
suppressor function may likely function in the nucleus. Transcription factors are an
obvious category of such targets that must act inside the nucleus by binding to their
cognate DNA elements and regulating the transcription of specific gene sets, often in
concert (141). Indeed, previous studies in cancer cells and non-cancer cell systems and
in vivo have identified a number of transcription factors as potential targets of CHIPmediated ubiquitylation and functional regulation. The known transcription factor targets
and the tissues/cell types in which these were found are indicated in Table 4.4. These
prior examples suggest examples, such as NFkappaB and others, that may be relevant
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to the tumor suppressor role of CHIP in ErbB2+ breast cancer. We however opted to
carry out an unbiased screen of CHIP-regulated transcription factors by assessing the
DNA-binding activities of transcription factors present in a commercially available array.
The Combi-Array from Affymetrix has an array of cognate DNA-binding sequences
corresponding to 345 transcription factors in a filter format that allows the analysis of the
levels of DNA-binding activities of corresponding transcription factors present in a
nuclear extract, using a work flow described in Chapter2. Although this assay measures
DNA-binding activity, and not the protein levels of transcription factors, we reasoned this
to be an advantage since examples of transcription factors that are regulated by CHIPdependent mono-ubiquitylation without degradation have been reported (142).
We carried out an analysis of relative DNA binding activities in nuclear extracts of
control vs. CHIP-overexpressing ErbB2+ BT474 breast cancer cell line, and expressed
the results as fold difference in binding activity (based on the intensity of spots on the
arrays), where the intensities of control spots were found to show the expected
invariance. As expected, the DNA-binding activities of most transcription factors did not
change beyond an arbitrary cu-off of 3-fold (Figure 4.4A). However, smaller subsets of
transcription factors present in the nuclear extracts of CHIP-overexpressing vs. control
cells showed more substantial increase or decrease in DNA-binding activities (Figure
4.4A), and we consider these as likely targets of CHIP, either as direct targets of
CHIPE3 ubiquitin ligase or as being regulated by other transcription factors or signaling
pathways that change the abundance or activities of these transcription factors.
Consistent with the robustness of our assay, the transcription factors identified as CHIPdepndent in our analysis (Table 4.4) included many transcription factors shown to be
downregulated by CHIP, such as p-53 and NFkB (143, 144).

4.5 MZF-1 is a direct target of CHIP-mediated ubiquitination and degradation
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Among the transcription factors identified by our screen, we focused on MZF-1

for a number of reasons, a primary one being its recent linkage to invasion signaling
downstream of ErbB2 (145). Myeloid zinc finger 1 (MZF-1) is a physiological regulator of
myeloid lineage development but has been linked to leukemia and more recently to solid
tumors (146-149). P55PIK transcriptionally activated by MZF-1 promotes colorectal
cancer cell proliferation (146). The MZF-1/c-MYC axis mediates lung adenocarcinoma
progression caused by wild-type lkb1 loss (148). Osteopontin mediates an MZF-1-TGFbeta1-dependent transformation of mesenchymal stem cells into cancer-associated
fibroblasts in breast cancer (149).
Efforts to identify mechanisms by which ErbB2 signaling leads to breast cancer
cell invasiveness in a 3D matrix culture identified a novel pathway in which ErbB2
signaling, via MZF-1, leads to transcriptional upregulation of cathepsin B (CTSB) and L
(CTSL). In this study, Cdc42-binding protein kinase beta, extracellular regulated kinase 2,
p21-activated protein kinase 4, and protein kinase C alpha were identified as essential
mediators of ErbB2-induced cysteine cathepsin expression and breast cancer cell
invasiveness.	
  This identified signaling network activates the transcription of cathepsin B
gene (CTSB) via myeloid zinc finger-1 transcription factor that binds to an ErbB2responsive enhancer element in the first intron of CTSB (145).
Our screen identified MZF-1 as one of the CHIP targets whose DNA-binding
activity was reduced upon CHIP overexpression in ErbB2-overexpressing breast cancer
c ell line BT474(Figure 4.4A; MZF-1 is highlighted as a red dot). To validate MZF-1 is a
transcription factor regulated by CHIP, we performed electrophoresis mobility shift assay
(EMSA) using double-stranded oligonucleotide probes corresponding to MZF-1 binding
sites on the promoters of CD34 genes (150). The level of binding, as seen in the
intensity of shifted bands on gels, between MZF-1 and its consensus DNA sequence
was indeed decreased in CHIP-overexpressing BT474 cells compared to control cells
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(Figure 4.4B). We further analyzed the mRNA and protein levels of MZF-1 in CHIPoverexpressing vs. control cells. Upon CHIP overexpression, both mRNA and protein
level of MZF-1 were decreased (Figure 4.4C and 4.4D). This result suggested that at
least part of the mechanism by which the DNA-binding activity of MZF-1 was reduced in
CHIP-overexpressing cells was indirect, via regulation of upstream modulators of MZF-1
transcription. However, to assess whether or not MZF-1 is also a target of direct
ubiquitination and degradation by CHIP we assessed the level of mZF-1 protein level
and its ubiquitination upon CHIP overexpression. We transfected MZF-1 and/or CHIP
plasmids into HEK-293T cells and analyzed the ubiquitination and degradation of MZF-1.
Immunoprecipitation of MZF-1 showed increased ubiquitination to be directly
proportional to ectopic CHIP levels (Figure 4.4E, upper). Correspondingly, the total level
of MZF-1 decreased upon increased expression of CHIP (Figure 4.4E, upper). All these
results therefore demonstrated that MZF-1 is ubiquitinated and degraded by CHIP. We
further assessed this question by testing the impact of expressing mutations in CHIP,
CHIPK30A (mutation in TPR domain and hence incapable of associating with
Hsp90/Hsc70) and CHIPH260Q (mutation in U-box domain and hence E3 deficient) (75),
on its ability to promote MZF-1 degradation. These analyses showed that intact TPR and
U-box domains were required for CHIP to reduce MZF-1 protein levels. These results
support the conclusion that MZF-1 is a bona-fide target of CHIP-dependent degradation.
In addition, we examined the extracellular matrix degradation by culturing cells
on FITC-labeled gelatins, which was a critical step for tumor metastasis. The
degradation of florescent gelatin was significantly decreased in CHIPOE cells (Figure
4.3E and 4.3F).

4.6 CHIP is a critical negative regulator of MZF-1-dependent Cathepsin B/L matrix
degradation axis
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Previously CTSB/L, key regulators of tumor progression and metastasis, have

been reported to be downstream transcriptional targets of MZF-1 and this axis has been
shown to hyperactivated by ErbB2 signaling (145). We therefore asked if the negative
regulation of MZF-1 by CHIP translates into altered expression of CTSB/L. We first used
the EMSA with DNA sequences corresponding to known MZF-1 binding site in the CTSB
promoter region as a probe. The binding activity of CTSB/L promoter region was
decreased in the nuclear extracts of CHIP-overexpressing cells compared to control
cells (Figure 4.5A). Importantly, both the mRNA and protein levels of CTSB and CTSL
were decreased upon CHIP overexpression (Figure 4.5B and 4.5C). Next, we used a
commercial kit (the Magic Red Kit) to test the functional enzymatic activity of CTSB and
CTSL in the CHIP-overexpressing vs. control ErbB2+ 21MT1 cell lines. CHIPoverexpressing cells showed reduced red fluorescence, which represents substrate
cleavage by CTSB/L, compared to control cells (Figure 4.5D). Quantification of red
fluorescence signals revealed that the levels of CTSB and CTSL activity were lower in
CHIP-overexpressing cells compared to control cells (Figure 4.5E). Overall, these results
establish that MZF-1/CTSB/L pro-invasion signaling axis is negatively regulated by CHIP.
The novel findings described above suggested that one mechanism by which
loss of CHIP promotes tumor progression is through upregulation of this key proinvasion/metastasis signaling pathway. We therefore investigated whether CTSB/L
inhibition would prevent or alleviate tumor progression and invasion. We utilized 21MT1
cells to test the impact of chemical inhibition of CTSB on cell invasion. The matrix
degradation assay using fluorescent collagen showed that CTSB inhibitor CA074 (151)
prevented matrix degradation (Figure 4.6A and 4.6B). Further, the colorimetric trans-well
invasion assay showed marked inhibition of cell invasion by CA074 (Figure 4.6C).
Next we tested the efficacy of CA074 in BT474 xenograft model, by treating mice
with CA074, Trastuzumab or their combination, since Trastuzumab is a standard
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targeted therapeutic antibody clinically used for ErbB2+ breast cancer. Treatment of
mice with CA074 resulted in a marked inhibition of tumor growth, comparable to that
seen with Trastuzumab, although the combination did not show a significant
additive/synergistic effect (Figure 4.6D). The likely explanation for the latter result
includes the fact that both drugs are being used at their optimal doses based on
previous studies (151). These results support the idea that one mechanism by which
loss of CHIP functions to promote ErbB2+ breast tumor progression (based on our
clinical-pathological studies) is by allowing increased MZF-1 dependent cathepsin
expression. Our results also support the potential targeting of cathepsin B, and
potentially CTSB/L together, as a future therapeutic approach against ErbB2+ breast
cancer where CHIP is downregulated, especially under metastatic settings.

4.7 Discussion
In this chapter, we used TMAs derived from the largest cohort studied for
analyses of CHIP protein expression in breast cancer to demonstrate that CHIP
expression is downregulated in nearly two-thirds ErB2+ and triple-negative subtypes of
breast cancers and in about a third of ER+ breast cancers. Analyses in cell lines
confirmed the predominant loss of CHIP expression in the former two subtypes of breast
cancer, and as in previous studies (83) suggested that loss of CHIP expression is
regulated at the level of mRNA levels. It will be of interest to examine if this is due to
suppression of transcription possibly due to hypermethylation of CHIP gene, due to
influence of altered regulatory RNAs such as microRNAs (152), or both. Since the ER+
subtype is the largest subtype of breast cancer, numerically the CHIP-low ER+ tumors
add to similar ErbB2+ and triple-negative cases with nearly half of all patients with breast
cancer exhibiting a loss of CHIP expression. Our clinical-pathological analyses suggest
that patients within this group carry an intrinsically poorer survival and increased tumor
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progression and metastasis. This is consistent with poorer intrinsic patient outcomes and
higher metastatic odds of patients with triple-negative and ErbB2+ breast cancers (83). It
will be of considerable future interest to further assess if the ER+ patients with low CHIP
expression belong to a particular molecular sub-classification of ER+ tumors; in this
regard, a potential candidate is the luminal B subtype of breast cancers which has
considerably poor survival and therapeutic responses compared to luminal A or normallike breast cancers (83). Thus, our clinical-pathological analyses, together with other
recent reports (83, 92), strongly supports the idea that CHIP is a tumor suppresser
whose expression is a barrier to tumor progression and metastasis in breast cancer.
Our study revealed a novel finding in that it is the loss of nuclear CHIP instead of
cytoplasmic CHIP that correlates with tumor progression markers and poorer survival.
We used this novel clinically-driven insight as a basis for an unbiased protein/DNA array
screen to identify a substantial group of transcription factors whose DNA-binding activity
is directly or indirectly regulated by CHIP (Figure 4.4A). This screen vastly expands the
list of potential targets of CHIP, beyond a few described in the literature (143, 144),
whose unregulated activity may contribute to oncogenesis in breast and other cancers.
As an in-depth analysis of all or most of the identified transcription factors would be
unfeasible within this study, we focused on a particularly novel and relevant candidate
MZF-1.
MZF-1 is a physiological regulator of myeloid lineage development but has been
linked to leukemia and more recently to solid tumors. A previous report exploring
mechanistic basis of ErbB2-driven invasion signaling in a 3D matrix culture identified a
novel pathway in which ErbB2 signaling impinges on via MZF1 to upregulate its ability to
transcribe specific invasion-mediated gene targets cathepsin B (CTSB) and L (CTSL)
(153). CTSB and CTSL have been shown to be overexpressed in primary breast cancer
tissues and knockdown of CTSB or MZF1 abrogated invasiveness in vitro. Since our
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study revealed MZF1 as one of the transcription factors whose DNA-binding activity was
downregulated by CHIP, we considered it as a particularly pertinent candidate for further
elucidation as a potential target of CHIP in ErbB2+ breast cancer.
Further analysis confirmed that MZF-1 was a direct target of CHIP for
ubiquitination (Figure 4.4D) but also revealed that MZF-1 levels may be regulated by
CHIP at the mRNA level, likely due to an impact of CHIP on upstream regulators of
MZF-1 expression, such as FOXM1, which is known to function upstream of MZF-1 and
showed reduced DNA-binding activity in CHIP-overexpressing cells. It remains possible
that additional CHIP-dependent negative regulation of MZF-1 activity may emanate from
negative regulation of upstream kinases, including ErbB2 itself, by CHIP as shown in
Chapter 3 and in previous studies (74, 75).
Consistent with a key role of CHIP in controlling the MZF-1-dependent
transcriptional network leading to CTSB/L expression, ErbB2+ breast cancer cell lines
express lower levels of CHIP compared to normal or ER+ breast cancer cell lines (such
as MCF-7) and correspondingly express high CTSB levels, which were markedly
reduced upon CHIP overexpression (Figure 4.5C). Conversely, knockdown of CHIP in
an ER+ breast cancer cell line, MCF7, markedly increased the CTSB levels (Figure
4.5D). The latter result is of interest as it suggests that the MZF-1/CTSB/L axis may be
activated by non-ErbB2 oncogenic drives as well, consistent with loss of CHIP
expression in triple-negative and a subset of ER+ breast cancers. Future studies to
identify oncogenic drivers distinct from ErbB2 that connect to MZF-1/CTSB/L pathway
will be of great significance.
Cathepsin B is a well-established downstream mediator of invasive/metastatic
signaling in various cancers, including breast cancer (145, 151). Targeting CTSB, using
a specific inhibitor CA074, decreased extracellular matrix degradation and cell invasion
in vitro and tumor growth in vivo (Figure 4.6). Thus, our studies using both genetic
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manipulations and pharmacological tools demonstrate that upregulation of MZF1/CTSB1/L axis is an important pro-oncogenic mechanism unleashed as a result of loss
of CHIP expression in ErbB2+ breast cancer. Given the well-established roles of
cathepsins in matrix remodeling, invasion, angiogenesis and metastatic spread of
tumors (145), we suggest that loss of CHIP expression promotes tumor progression into
an invasive/metastatic disease in part through cathepsin upregulation.
Metastasis is the ultimate cause of death among a vast majority of cancer
patients (154). Mechanisms that promote metastases are intricately linked to
therapeutic resistance (155), reflecting successful tumor cell adaptations (154, 156, 157).
A major adaptive mechanism is the upregulation of the HSP90/HSC70-depndent
molecular chaperone pathways that helps maintain protein folding and function in the
face of increased metabolic needs (34). This chapter identifies the mechanisms by which
alterations of this pathway provide a decisive component of this adaptation, involving
loss of expression of a negative co-chaperone CHIP to relax the protein quality control in
tumor cells in order to maintain the oncogenic drive. Our unbiased screen in ErbB2+
breast cancer cells has defined a previously known transcriptional pathway involved in
promoting metastatic signaling in ErbB2+ breast cancer cells as well as in other
malignancies. This transcriptional axis provides a novel therapeutic approach by
targeting its key metastasis-relevant downstream targets, such as CTSB/CTSL. Thus,
the use of CTSB inhibitor CA074 could suggest a new approach to prevent or treat
metastases in ErbB2+ breast cancers, and help to prevent or overcome therapeutic
resistance. Expression of CHIP may also serve as a biomarker to select patients likely to
benefit from such therapy. Current antibody-based therapy of ErbB2+ cancers is
ineffective against brain metastases and availability of small molecules against CTSB/L
could help address this key issue. While this study focused on ErbB2+ breast cancer,
loss of CHIP expression is also a key event in two-thirds of triple-negative and one-third

	
  
of ER+ (which together outnumber the CHIP-lo ErbB2+ breast cancers). Together, the
ErbB2+ and triple-negative breast cancers, while a minority of all breast cancers,
account for the majority of deaths due to breast cancer, the most common malignancy
and the second leading cause of cancer deaths among women. Loss of CHIP
expression is also becoming identified as a mechanism of oncogenic progression in
other cancers such as colorectal, pancreas and lung cancer (84, 96, 144, 158, 159).
Thus mechanisms we identified in this study will impact a broad range of human
malignancies.
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Figure 4.1. Decreased nuclear CHIP staining in breast cancer patients.
(A) Representative IHC staining patterns of CHIP. (B) Kaplan-Meier curves
survival analysis of CHIP expression in breast cancer. (C) The CHIP mRNA level in the
whole panel of breast cancer cell lines. Total RNA was extracted from cells and followed
by RT-PCR reactions. GAPDH was used as a normalization control. (D) The CHIP
protein level in the whole panel of breast cancer cell lines by western blotting. Hsc70
was loading the control. (E) Generation of stable CHIPOE breast cancer cell lines.
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Figure 4.2. CHIP overexpression suppresses tumor growth in a mouse xenograft
model.
(A) Tumor growth curves in nude mice inoculated with control and CHIPOE BT474
cells. (B) Representative tumors were shown, upper panel from control cells, lower panel
from CHIPOE cells. (C) Expression level of CHIP in xenograft tumor cells was analyzed
by immunoblotting. (D, E) Sections of tumor from mice injected with control and CHIPOE
cells were stained with hematoxylin and eosin (H&E, E) or labeled with Ki67 (brown
staining) and cleaved caspase 3 (red staining) (Ki67 and CC3, D). (F, G) Quantification
of Ki67 (F) and CC3 (G) positive cells in Figure D and E. Bars represents mean + S.D.
(n=6).
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Figure 4.3. CHIP overexpression suppresses oncogenesis in ErbB2+ cells.
(A) Accumulative proliferation of control and CHIPOE 21MT1 cells. Growth rate
were measured by MTT assay. (B) Decreased anchorage-independent cell growth in
CHIPOE cells. Cells were seed in soft agar plates and incubated for 3 weeks. Colonies
were stained, imaged and analyzed under microscope. (C, D) Decreased migration and
invasion by CHIP overexpression. Cells were seed onto filters with 8-µm pore size in
uncoated (C, migration) or Matrigel- coated (D, invasion) upper chambers. Average
numbers of cells that migrated or invaded are shown. (E) Decreased extracellular matrix
degradation in CHIPOE cells. Cells were seed on top of FITC-labeled gelatin in glass
chamber and incubated for 48 hours. Cells were fixed and stained with invadipodia and
DAPI and imaged under fluorescent microscope. The black hole represents degraded
extracellular matrix. (F) Quantification of degraded extracellular matrix. Data represent
mean + S.D., n=3.
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Figure 4.4. CHIP regulates transcription factor activity and MZF-1 is one of the
targets.
(A) Analysis of DNA-binding activities of 345 transcription factors in control vs.
CHIPOE ErbB2+ BT474 cell line by Panomics Combo-array (Affymatrix). Y-axis
represents log-fold binding in CHIPOE over control cells. MZF-1 is highlighted in red. (B)
MZF-1 binding activity decreased in CHIPOE cells. Biotin-labeled MZF-1 consensus DNA
sequence was used as probe and loaded with nuclear extracts from CHIPOE and control
cells to carry out EMAS. 200 fold higher non-biotin-labeled consensus sequence served
as competitor. (C, D) MZF-1 mRNA and protein level decreased in CHIPOE cells. Total
RNA was prepared from BT474 cells and MZF-1 mRNA level was quantified using realtime RT-PCRs (C), protein level was analyzed by immunoblotting (D). (E) Ubiquitination
and degradation of MZF-1 is induced by CHIP. GFP-tagged MZF-1 and Myc-tagged
CHIP (0, 0.5, 4ug) were transfected into HEK293t cells. MZF-1 was immuoprecipitated
by using anti-MZF-1 antibody, ubiquitin and MZF-1 was detected in immuoprecipitants
(upper panel) and MZF-1, CHIP and Hsc70 were detected in whole cell lysates (lower
panel).
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Figure 4.5. CTSB/L is the downstream target of CHIP-MZF-1 axis.
(A) The binding activity of CTSB promoter region is decreased in CHIPOE BT474
cells. Biotin-labeled CTSB promoter region DNA sequence was used as probe and
loaded with nuclear extracts from CHIPOE and control cells to carry out EMAS. 200 fold
higher non-biotin-labeled consensus sequence served as competitor. (B, C) CTSB/L
mRNA and protein level decreased in CHIPOE cells. Total RNA was prepared from
BT474 cells and CTSB/L mRNA level was quantified using real-time RT-PCRs (C),
protein level was analyzed by immunoblotting. (D) CTSB/L activity decreased in CHIPOE
cells. Cells were seed on cover slips and incubated with CTSB/L substrates for 1 hour,
fixed and stained with DAPI, imaged were took under fluorescent microscope. Red
fluorescence represents CTSB/L cleavage products. (E, F) Quantification of red
fluorescence in Figure D. Data represents mean+ S.D., n=3.
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Figure 4.6. CTSB inhibition decreased ErbB2+ cell progression.
(A) CTSB inhibition decreased extracellular matrix degradation in 21MT1 cells.
Cells were seed on top of FITC-labeled gelatin in glass chamber and incubated with
DMSO or CA074 for 48 hours. Cells were fixed and stained with invadipodia and DAPI
and imaged under fluorescent microscope. The black hole represents degraded
extracellular matrix. (B) Quantification of degraded extracellular matrix. Data represent
mean + S.D., n=3. (C) CTSB inhibition decreased 21MT1 cell invasion. Cells were seed
on top of marigel-coated membrane in 96-well plated, and incubated with DMSO or
CA074 for 24 hours. Invading cells were trypsinized, stained and read under fluorescent
reader. (D) CTSB inhibition decreased tumor growth in xenograft model. BT474 cells
were inculcated under fatpad of nude mice. Saline/Trastuzumab was injected through
tail vein at the dose of 4mg/kg every four days. CA074 was intraperitoneally injected
daily at 25mg/kg. Tumor volumes were monitored every other day. Data represents
mean + S.E., n=4.

	
  

96

	
  
Table 4.1 The association between Nuclear (N) CHIP and clinicopathological
variables in the whole series.
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Clinicopathological
variables

N-CHIP
Negative/ low expression,
N (%)

Age (years)
<50
>50
Menopausal status
Pre
Post
Tumour Size
<2 CM
>2CM
Tumour Grade
1
2
3
Tubule formation
1
2
3
Pleomorphism
1
2
3
Mitosis
1
2
3
Lymph Node Stage
1
2
3
Lymphovascular invasion
(LVI)
No
Definite
Nottingham Prognostic
Index
Mild
Moderate
High

High expression, N (%)

p-value

231(35.1%)
427(64.9%)

100(31.8%)
214(68.2%)

0.316

248(37.8%)
408(62.2%)

121(38.7%)
192(61.3%)

0.798

89(44.5%)
361(55.5%)

168(53.5%)
146(46.5%)

0.008

66(10.2%)
194(29.9%)
388(59.9%)

72(22.9%)
126(40.1%)
116(36.9%)

1×10-7

23(3.7%)
187(29.8%)
417(66.5%)

23(7.5%)
117(38.1%)
167(54.4%)

4×10-4

11(1.8%)
196(31.4%)
418(66.9%)

6(2.0%)
155(50.5%)
146(47.6%)

1×10-7

157(25.0%)
117(18.7%)
353(56.3%)

148(48.2%)
63(20.5%)
96(31.3%)

1×10-7

398(61.4%)
195(30.1%)
55(8.5%)

192(61.1%)
101(32.2%)
21(6.7%)

0.558

418(64.5%)
230(35.5%)

202(64.5%)
111(35.5%)

0.993

147(23.8%)
368(59.5%)
103(16.7%)

126(41.7%)
144(47.7%)
32(10.6%0

1×10-7

	
  
Table 4.2: The association between Nuclear (N) CHP and different proteins related
to ER and HER2 pathways in the whole series.
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N-CHIP
Negative/low expression,
High expression, N (%)
N (%)
Hormon receptors
Oestrogen receptor (ER)
Negative
Positive
Progesterone receptor (PgR)
Negative
Positive
Androgen receptor (AR)
Negative
Positive
Triple negative status
Non TN
TN
Basal phenotype
Negative
Positive
Other ER related proteins
CK7/8
Negative
Positive
CK18
Negative
Positive
CK19
Negative
Positive
E-Cadherin
Negative
Positive
p-Cadherin
Negative
Positive
N-Cadherin
Negative
Positive
Tumour suppressor proteins
p53
Negative/low
Positive
BRCA1
Negative/low
High
Proliferation markers
KI67-LI
Negative/low
High
Apoptosis related markers
BCL2
Negative/low
High

p-value

207(31.7%)
447(68.3%)

44(14.2%)
266(85.8%)

1×10-7

296(47.0%)
334(53.0%)

97(32.1%)
205(67.9%)

1×10-5

272(6.5%)
313(53.5%)

65(23.7%)
209(76.3%)

1×10-7

497(78.1%)
139(21.9%)

276(89.9%)
31(10.1%)

528(82.8%)
110(17.2%)

285(92.5%)
23(7.5%)

12(1.9%)
621(98.1%)

3(1.0%)
297(99.0%)

0.310

2(16.2%)
476(83.8%)

22(7.9%)
258(92.1%)

0.001

63(10.2%)
554(89.8%)

16(5.4%)
283(94.6%)

0.014

235(38.1%)
382(61.9%)

104(35.0%)
193(65.0%)

0.368

229(43.8%
294(56.2%)

144(56.9%)
109(43.1%)

0.001

107(22.3%)
372(77.7%)

78(34.7%)
147(65.3%)

0.001

423(67.9%)
200(32.1%)

228(77.3%)
67(22.7%)

0.003

266(52.3%)
243(47.7%0

87(34.0%)
169(66.0%)

2×10-6

171(33.5%)
339(66.5%)

138(54.8%)
114(45.2%)

1×10-7

219(44.6%)
272(55.4%)

71(32.7%)
146(67.3%)

1×10-5
5×10-5

0.003
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HER family proteins
HER1
Negative
Positive
HER2
Negative
Positive
HER3
Negative
Positive
HER4
Negative
Positive

482(76.0%)
152(24.0%)

254(83.6%)
50(16.4%)

0.009

521(82.6%)
110(17.4%)

273(90.7%)
28(9.3%)

0.001

44(7.5%)
539(92.5%)

30(10.8%)
248(89.2%)

0.112

65(10.4%)
560(89.6%)

50(16.4%)
254(83.6%)

0.009

	
  
Table 4.3 The association between cytoplasmic CHIP and the clinicopathological
variables in the whole series
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Negative/low
expression, N (%)
Hormon receptors
Oestrogen receptor (ER)
Negative
Positive
Progesterone receptor (PgR)
Negative
Positive
Androgen receptor (AR)
Negative
Positive
Triple negative status
Non TN
TN

C-CHIP
High expression, N (%)

p-value
0.110

151(28.0%)
388(72.0%)

98(23.4%)
320(76.6%0

216(41.7%)
302(58.3%)

175(43.0%)
232(57.0%)

193(40.9%)
279(59.1%)

142(37.4%)
238(62.6%)

0.296

415(79.3%)
108(20.7%)

352(85.2%)
61(14.8%)

0.020

375(71.0%)
153(29.0%)

321(77.7%)
92(22.3%)

0.024

11(2.1%)
509(97.9%)

4(1.0%)
402(99.0%)

0.176

78(16.9%)
384(83.1%)

34(9.0%)
345(91.0%)

0.001

47(9.3%)
461(90.7%)

31(7.7%)
3709(92.3%)

0.416

186(36.7%)
321(63.3%)

153(38.3%)
247(61.8%)

0.629

190(46.0%)
223(54.0%)

182(50.8%)
176(49.2%)

0.180

107(28.1%)
274(71.9%)

75(23.7%)
242(76.3%)

0.185

350(68.8%)
159(31.2%)

297(73.9%)
105(26.1%)

0.091

187(45.3%)
226(54.7%)

165(47.6%)
182(52.4%)

0.532

176(41.4%)
249(58.6%)

130(39.3%)
201(60.7%)

0.553

0.691

Basal phenotype

CK7/8
Negative
Positive
CK18
Negative
Positive
CK19
Negative
Positive
E-Cadherin
Negative
Positive
p-Cadherin
Negative
Positive
N-Cadherin
Negative
Positive
p53
Negative/low
Positive
BRCA1
Negative/low
High
Proliferation markers
KI67-LI
Negative/low

	
  
High
Apoptosis related markers
BCL2
Negative/low
High
HER1
Negative
Positive
HER2
Negative
Positive
HER3
Negative
Positive
HER4
Negative
Positive
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165(40.8%)
239(59.2%)

123(41.3%)
175(58.7%)

0.908

419(80.0%)
105(20.0%)

311(76.4%)
96(23.6%)

0.192

455(87.7%)
64(12.3%)

333(82.0%)
73(18.0%)

0.016

50(10.5%)
428(89.5%)

24(6.4%)
352(93.6%)

0.036

67(13.0%)
450(87.0%)

47(11.6%)
358(88.4%)

0.535

	
  
Table 4.4: The list of transcription factors which activity were downregulated by
CHIP overexpression in ErbB2+ BT474 cells
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.
ACPBP
ADD-1
ADR-1
ALF-1
alpha-PAL
AML-1
ARP
ATF
ATF adelta
ATF-a
c-Rel
CACC
CCAAT
CEBP
CEF-2
COUP-TF
CTCF
E12

E12/E47
E2
EGR-1
EKLF
ETF
Freac-2
Freac-4
GAG
GBF-1/2/3/HY5
H4TF-1
HFH-1
HFH-3
HFH-8
HIF-1
HNF-3
HNF-4a
ISGF
Isl-1

L-lll BP
Lactoferrin-BP
LF-A1
LSF
LXRF-1
MEF-1
MRE
MT-box
MTF
MUSF-1
MyoD
MZF-1
NF-1
NF-1/2
NF-4FA
NF-Atx
NF-E1/YY1
NF-E2

NF-E6/CP1
NF-Y
NFkB
p-53
PAX-2
PAX-4
PAX-5
PAX-6
PBGD BP
Pbx1
PCF
PEBP-2
PPUR
PPUR
PRDll-BF1
PUR
RAR/DR-5
RB
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Chapter 5: Conclusions and future directions

	
  

108

5.1 Conclusions
Taken all together, we demonstrated a novel role of E3 ubiquitin ligase CHIP in
regulating ErbB2-mediated oncogenesis in breast cancer. Previously our laboratory
reported that CHIP was the E3 ligase that mediated ErbB2 degradation upon Hsp90
inhibition. However, further analysis of CHIP KD in cells did not abolish ErbB2
degradation when treated with Hsp90 inhibitor 17AAG. Instead, we observed higher cell
surface ErbB2 level in CHIP KD cells. A functional role of CHIP in protein quality control
suggested that CHIP may regulate ErbB2 during its maturation. In support of this
hypothesis, we show that CHIP downregulates immature ErbB2 by enforcing its ERAD
pathway (Figure 5.1). In addition, loss of CHIP promotes an increase in ER stress in
ErbB2+ breast cancer cells, which sensitizes these tumor cells to further ER stress
induction by a clinically-used drug, the proteasome inhibitor bortezomib. Notably, the
combination of bortezomib with trastuzumab, a FDA-proved standard therapeutic
monoclonal antibody targeted against ErbB2+ breast cancer, showed synergistic growth
inhibition in ErbB2+ breast cancer cells.
Consistent with recent and our clinical studies, which support a tumor
suppressor function of CHIP in ErbB2+ breast cancers, we constructed stable CHIP
overexpressing breast cancer cell lines and illustrated CHIP as a suppressor of ErbB2+
tumor growth and metastasis in vitro and in vivo. We undertook an extensive clinicalpathological study of an extensively well-annotated breast cancer tissue bank to address
the variant conclusions of previous studies on whether CHIP is a prognosticator of poor
or better survival (83, 92, 93). Given the size of our study, our findings conclusively
demonstrate that loss of CHIP is a key pro-tumor progression adaptation in breast
cancer. Importantly, our studies showed that it is the loss of nuclear staining of CHIP,
observed in two thirds of ErbB2+ and triple-negative and one third of ER+ patients, that
significantly correlated with poor patient outcome, notably increased tumor grade, tumor
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size, mitosis, vascular invasion and lower breast cancer-specific survival at 15 years. To
explore the mechanism of how nuclear CHIP functions in ErbB2+ breast cancer, we
conducted an unbiased screen of DNA-binding activity of 345 transcription factors using
a commercial Protein/DNA array. Myeloid zinc finger 1(MZF-1) was identified and
validated as one of the direct target of CHIP. Further analysis of MZF-1downstream
target genes CTSB/CTSL revealed the novel CHIP-MZF-1-CTSB/CTSL pro-invasion
signaling axis recently identified downstream of ErbB2 (145) to be a key pathway
controlled by the levels of expression of CHIP in ErbB2+ breast cancer (Figure 5.1).
Targeting CTSB by using a specific chemical inhibitor CA074 in an ErbB2+ breast
cancer xenograft model demonstrated that targeting MZF1-CTSB/L axis in CHIP-low
ErbB2+ breast cancer is a potential therapeutic strategy. Given our findings that MZF-1CTSB/L axis is also unleashed by loss of CHIP in ER+ breast cancer cells, it is likely that
our findings and their therapeutic implications will be directly applicable to other
malignancies in which CHIP expression is downregulated as a tumor adaptation. Overall,
mechanistic and initial preclinical analyses presented in this thesis should provide a

basis for future strategies to improve therapeutics of ErbB2+ and other breast
cancers with downregulation of CHIP E3 expression by targeting a novel
pathway identified here to be regulated by CHIP.

5.2 Future directions
In this thesis, we investigated the tumor suppressor role of E3 ubiquitin ligase
CHIP in ErbB2+ breast cancer. We identified a novel MZF-1-CTSB/L pathway in ErbB2mediated tumor progression and metastasis from an unbiased transcription factor screen
(Figure 4.4A). Aside from MZF1, which was analyzed here, the large subset of analyzed
transcription factors that was downregulated by CHIP included HNF-3 (FoxM1) an
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important candidate of clinical relevance. FoxM1 overexpression has been linked to
EMT, metastasis and resistance to chemotherapy, trastuzumab and lapatinib in ErbB2+
breast cancers (155, 160-163), and is overexpressed in breast tumor tissues. It is
reasonable to anticipate that transcription activity of FoxM1 is also regulated by CHIP
and its upregulation upon loss of CHIP expression may be a key factor in breast cancer
progression. It will be of considerable interest to explore this avenue.
Cancer stem cells (CSCs) have several distinct characteristics, including high
metastatic potential, tumor-initiating potential and properties that resemble normal stem
cells such as self-renewal, differentiation and chemotherapy drug efflux (143, 164).
Because of these characteristics, CSCs are considered to be responsible for cancer
initiation, progression and metastasis. Recently, CHIP was reported to be reduced CSCs
in a population of breast cancer cells (165). CHIP depletion resulted in an increased
proportion of CSCs among breast cancer cells. The molecular mechanism of how CHIP
regulates CSC properties in breast cancer is unknown. However, from our protein/DNA
array screening PAX2, c-Myc and p53 transcription factors provide potential candidates
as these have been identified to be downregulated by CHIP. These transcription factors
are thought to positively regulate CSCs. (166-170). Hence, further validating these
factors in breast cancers and performing tumor spheres assays may elucidate the
relationship between CHIP and CSCs.
As the link of MZF-1 to breast cancer is relatively new, it will be of great interest
to assess the importance of this transcription factor in breast cancer oncogenesis and
metastasis using human cell line and genetically-modified mouse models of breast
cancer.
Our studies revealed a key role of CHIP in regulating ErbB2 ERAD, but curiously
revealed the block to ErbB2 transport to be primarily at the Golgi. It will be of great
interest to further examine if indeed the ERAD-associated biochemical cascade is
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indeed involved in CIP-dependent degradation of ErbB2 in the ER as well as potentially
at the Golgi. Such studies will require fractionation of different pools of ErbB2 and
assessment of their CHIP-dependent ubiquitination, and interaction with Hsp90/Hsc70
molecular chaperones as ERAD apparatus.
Finally, it will be of considerable importance to further validate the findings
presented here in a broader panel of human breast cancer cell line models and in
genetically-modified mouse models where the impact of MZF-1-CTSB/L proinvasion/metastasis axis can be more critically examined in an environment of an intact
immune system in models that show various components of metastatic disease aside
from primary tumorigenesis.
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Figure 5.1 The working model of how CHIP regulates ErbB2 mediated
oncogenesis
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